CA2672551A1 - Biodegradable block copolymeric compositions for drug delivery - Google Patents
Biodegradable block copolymeric compositions for drug delivery Download PDFInfo
- Publication number
- CA2672551A1 CA2672551A1 CA002672551A CA2672551A CA2672551A1 CA 2672551 A1 CA2672551 A1 CA 2672551A1 CA 002672551 A CA002672551 A CA 002672551A CA 2672551 A CA2672551 A CA 2672551A CA 2672551 A1 CA2672551 A1 CA 2672551A1
- Authority
- CA
- Canada
- Prior art keywords
- peg
- drug
- biodegradable
- composition
- block
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 158
- 238000012377 drug delivery Methods 0.000 title abstract description 33
- 229920001577 copolymer Polymers 0.000 title description 38
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 159
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 158
- 229920001400 block copolymer Polymers 0.000 claims abstract description 59
- 239000003937 drug carrier Substances 0.000 claims abstract description 39
- 239000000084 colloidal system Substances 0.000 claims abstract description 21
- 239000012456 homogeneous solution Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 89
- 229940079593 drug Drugs 0.000 claims description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- -1 D-lactide Chemical compound 0.000 claims description 29
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 20
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 18
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 16
- 229920001710 Polyorthoester Polymers 0.000 claims description 16
- 239000002745 poly(ortho ester) Substances 0.000 claims description 16
- 229920000229 biodegradable polyester Polymers 0.000 claims description 13
- 239000004622 biodegradable polyester Substances 0.000 claims description 13
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 12
- 150000002905 orthoesters Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 5
- 229930182843 D-Lactic acid Natural products 0.000 claims description 5
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 229940022769 d- lactic acid Drugs 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical class CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001248 thermal gelation Methods 0.000 claims description 4
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 4
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 20
- 239000008135 aqueous vehicle Substances 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 34
- 239000007788 liquid Substances 0.000 description 28
- 230000002209 hydrophobic effect Effects 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 16
- 229920000428 triblock copolymer Polymers 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- 229920000747 poly(lactic acid) Polymers 0.000 description 11
- 239000013543 active substance Substances 0.000 description 9
- 229920000359 diblock copolymer Polymers 0.000 description 9
- 230000009969 flowable effect Effects 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- ZNCFMBOWBMPEAC-UHFFFAOYSA-N 3,9-di(ethylidene)-2,4,8,10-tetraoxaspiro[5.5]undecane Chemical compound C1OC(=CC)OCC21COC(=CC)OC2 ZNCFMBOWBMPEAC-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 229920001600 hydrophobic polymer Polymers 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002077 nanosphere Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 101150045754 aba3 gene Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 235000021463 dry cake Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940063149 nutropin Drugs 0.000 description 2
- 238000012643 polycondensation polymerization Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 229940094938 stannous 2-ethylhexanoate Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940000031 blood and blood forming organ drug Drugs 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003177 water-insoluble biodegradable polymer Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/002—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2261/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G2261/10—Definition of the polymer structure
- C08G2261/12—Copolymers
- C08G2261/126—Copolymers block
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
- C08G2650/42—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group containing orthoester groups
Abstract
An improved drug delivery composition and method of use is disclosed.
The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative. The composition can be administered as is or after being be dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system.
The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative. The composition can be administered as is or after being be dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system.
Description
'= 1 BIODEGRADABLE BLOCK COPOLYMERIC COMPOSITIONS FOR DRUG DELIVERY
This is a division of Canadian Patent Application Serial No. 2,489,771, filed on May 29, 2003.
BACKGROUND OF THE INVDNTION
Field of the Invention The present invention relates to a composition for drug delivery. More specifically, the present invention relates to a copolymeric composition comprising a liquid polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and PEG derivative; and a biodegradable block copolymeric drug carrier. Particularly, this invention relates to compositions comprising a polyethylene glycol (PEG), PEG derivatives, or a mixture of a PEG and a PEG
derivative, and biodegradable ABA, BAB and AB type block copolymers that are based on biodegradable hydrophobic polyester or poly(ortho ester) A blocks and hydrophilic polyethylene glycol (PEG) B blocks.
Related Art Biodegradable polymers have been used as surgical sutures, wound dressings, and as drug delivery systems. Among them, polylactide (PLA), polyglycolide (PGA) and their copolymers (PLGA) have attracted the most attention. One example of a biodegradable polymeric drug delivery system is a system wherein a drug is contained in a biodegradable polymer matrix that is surgically implanted, which is a big disadvantage. In the form of injectable drug delivery systems, polymeric microspheres and nanospheres are known in the art.
Commercially available drug delivery formulations based on PLGA microspheres include Lupron Depot and Nutropin Depot . Microsphere and nanosphere systems have disadvantages in that they require special and complex preparation methods. Unfortunately, manufacturing microsphere and nanosphere dosage forms requires use of toxic or dangerous solvents (e.g., methylene chloride, ethyl acetate) and elaborate procedures (e.g., double emulsions, or cryogenic spraying techniques). The batch size is usually small and the cost is high. In addition, since PLGA biodegradable polymers used can only be dissolved in organic solvents
This is a division of Canadian Patent Application Serial No. 2,489,771, filed on May 29, 2003.
BACKGROUND OF THE INVDNTION
Field of the Invention The present invention relates to a composition for drug delivery. More specifically, the present invention relates to a copolymeric composition comprising a liquid polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and PEG derivative; and a biodegradable block copolymeric drug carrier. Particularly, this invention relates to compositions comprising a polyethylene glycol (PEG), PEG derivatives, or a mixture of a PEG and a PEG
derivative, and biodegradable ABA, BAB and AB type block copolymers that are based on biodegradable hydrophobic polyester or poly(ortho ester) A blocks and hydrophilic polyethylene glycol (PEG) B blocks.
Related Art Biodegradable polymers have been used as surgical sutures, wound dressings, and as drug delivery systems. Among them, polylactide (PLA), polyglycolide (PGA) and their copolymers (PLGA) have attracted the most attention. One example of a biodegradable polymeric drug delivery system is a system wherein a drug is contained in a biodegradable polymer matrix that is surgically implanted, which is a big disadvantage. In the form of injectable drug delivery systems, polymeric microspheres and nanospheres are known in the art.
Commercially available drug delivery formulations based on PLGA microspheres include Lupron Depot and Nutropin Depot . Microsphere and nanosphere systems have disadvantages in that they require special and complex preparation methods. Unfortunately, manufacturing microsphere and nanosphere dosage forms requires use of toxic or dangerous solvents (e.g., methylene chloride, ethyl acetate) and elaborate procedures (e.g., double emulsions, or cryogenic spraying techniques). The batch size is usually small and the cost is high. In addition, since PLGA biodegradable polymers used can only be dissolved in organic solvents
2 their preparation requires the use of such solvents which are foreign and harmful to the human body, and cannot be completely removed during manufacture by any known method.
Furthermore, some drugs such as peptides and proteins may lose their pharmacological activity after contact with organic solvents.
An improvement to the aforementioned drug delivery systems is an in situ formed depot based on PLGA as disclosed in U.S. Patent 5,599,552. In that system, PLGA is dissolved in water-soluble organic solvent(s), such as N-methyl-2-pyrrolidone, and the drug is either suspended or dissolved in this polymeric solution. The solution can be injected subcutaneously to form an in situ depot to trap the drug in the polymer that precipitates as the organic solvent diffuses away. However, the drawback is the requirement for an organic solvent that is used to dissolve the biodegradable PLGA polymer. Organic solvents, such as N-methyl-2-pyrrolidone, are foreign to the human body and can cause unwanted side effects both acutely and chronically.
U.S. Patent 5,543,158 discloses nanoparticles or microparticles formed from a water-insoluble block copolymer consisting essentially of poly(alkylene glycol) and poly(lactic acid).
The molecular weight of the block copolymer is high and the copolymer is insoluble in water.
In the nanoparticle or microparticle, the biodegradable moieties of the copolymer are in the core of the nanoparticle or microparticle and the poly(alkylene glycol) moieties are on the surface of the nanoparticle or microparticle in an amount effective enough to decrease uptake of the nanoparticle or microparticle by the reticuloendothelial system.
Nacloparticles are prepared by dissolving the block copolymer and drug in an organic solvent, forming an o/w emulsion by sonication or stirring, and collecting the nanoparticles containing the drug following precipitation.
Currently there are few synthetic or natural polymeric materials that can be used for the controlled delivery of drugs, including peptide and protein drugs, because of strict regulatory compliance requirements such as biocompatibility, low toxicity, having a clearly defined
Furthermore, some drugs such as peptides and proteins may lose their pharmacological activity after contact with organic solvents.
An improvement to the aforementioned drug delivery systems is an in situ formed depot based on PLGA as disclosed in U.S. Patent 5,599,552. In that system, PLGA is dissolved in water-soluble organic solvent(s), such as N-methyl-2-pyrrolidone, and the drug is either suspended or dissolved in this polymeric solution. The solution can be injected subcutaneously to form an in situ depot to trap the drug in the polymer that precipitates as the organic solvent diffuses away. However, the drawback is the requirement for an organic solvent that is used to dissolve the biodegradable PLGA polymer. Organic solvents, such as N-methyl-2-pyrrolidone, are foreign to the human body and can cause unwanted side effects both acutely and chronically.
U.S. Patent 5,543,158 discloses nanoparticles or microparticles formed from a water-insoluble block copolymer consisting essentially of poly(alkylene glycol) and poly(lactic acid).
The molecular weight of the block copolymer is high and the copolymer is insoluble in water.
In the nanoparticle or microparticle, the biodegradable moieties of the copolymer are in the core of the nanoparticle or microparticle and the poly(alkylene glycol) moieties are on the surface of the nanoparticle or microparticle in an amount effective enough to decrease uptake of the nanoparticle or microparticle by the reticuloendothelial system.
Nacloparticles are prepared by dissolving the block copolymer and drug in an organic solvent, forming an o/w emulsion by sonication or stirring, and collecting the nanoparticles containing the drug following precipitation.
Currently there are few synthetic or natural polymeric materials that can be used for the controlled delivery of drugs, including peptide and protein drugs, because of strict regulatory compliance requirements such as biocompatibility, low toxicity, having a clearly defined
3 degradation pathway, and safety of the polymers and degradation products. The most widely investigated and advanced biodegradable polymers in regard to available toxicological and clinical data are the aliphatic poly(a-hydroxy acids), such as poly(D-, L- , or D, L- lactic acid) (PLA), poly(glycolic acid) (PGA) and their copolymers (PLGA). These polymers are commercially available and are presently used as bioresorbable sutures and in biodegradable microsphere drug delivery systems. FDA-approved microsphere systems for controlled release of leuprolide acetate (Lupron DepotT"') and human growth hormone (Nutropin DepotTM) are based on PLGA copolymers. Based on this history of use, PLGA copolymers have been the materials of choice in the initial design of parenteral controlled release drug delivery systems using a biodegradable carrier.
Even tliough there has been some limited success, biodegradable block copolymers that are based on biodegradable polyester or poly(ortho ester) and polyethylene glycol (PEG) blocks, when used as drug carriers, present problems that are associated with their physicochemical properties and attendant methods of fabrication. For example, biodegradable block copolymers are, by design, not stable in aqueous environments although shelf-lives of several years can be achieved when they are stored frozen. However, elimination of cold storage requirements would be advantageous in most instances. It is also desirable to gain further advantages related to rapid dissolution of neat block copolymers into aqueous vehicles at normal or ambient room temperature conditions. Rapid dissolution of the block copolymers peimits reconstitution at time-of-use to occur, which in tum permits room temperature storage of neat block copolymers.
Known water soluble block copolymers are slow to dissolve in water, often requiring several hours for complete dissolution to occur. Compositions that show accelerated dissolution kinetics are desired.
Some drugs, such as proteins, are stable in aqueous solutions for only short periods. To compensate for this short-term stability, these drugs are commonly formulated as dry cakes and
Even tliough there has been some limited success, biodegradable block copolymers that are based on biodegradable polyester or poly(ortho ester) and polyethylene glycol (PEG) blocks, when used as drug carriers, present problems that are associated with their physicochemical properties and attendant methods of fabrication. For example, biodegradable block copolymers are, by design, not stable in aqueous environments although shelf-lives of several years can be achieved when they are stored frozen. However, elimination of cold storage requirements would be advantageous in most instances. It is also desirable to gain further advantages related to rapid dissolution of neat block copolymers into aqueous vehicles at normal or ambient room temperature conditions. Rapid dissolution of the block copolymers peimits reconstitution at time-of-use to occur, which in tum permits room temperature storage of neat block copolymers.
Known water soluble block copolymers are slow to dissolve in water, often requiring several hours for complete dissolution to occur. Compositions that show accelerated dissolution kinetics are desired.
Some drugs, such as proteins, are stable in aqueous solutions for only short periods. To compensate for this short-term stability, these drugs are commonly formulated as dry cakes and
4 powders that can be stored under water-free conditions for much longer periods. Immediately prior to administration the dry cake or powder is reconstituted with an aqueous vehicle. Thus the situation is frequently encountered where it is desirable to have both the drug and the block copolymer drug delivery system formulated in reconstitutable forms. To be facile, it is critical that reconstitution, i.e., dissolution of the block copolymers and drug be completed in a short period.
U.S. Patent No. 5,384,333 discloses an injectable drug delivery composition in which a pharmacologically active substance is contained in a copolymer comprising a hydrophilic part and a hydrophobic part. However, the composition has to be heated to a relatively high temperature such as 38 C to 52 C, immediately before use and it is difficult to uniformly distribute the drug in the polymeric composition. U.S. Patent No. 5,612,052 discloses a block copolymer composition that when contacted with water forms a hydrogel.
However, the drug incorporated in this composition is rapidly released. U.S. Patent No.
U.S. Patent No. 5,384,333 discloses an injectable drug delivery composition in which a pharmacologically active substance is contained in a copolymer comprising a hydrophilic part and a hydrophobic part. However, the composition has to be heated to a relatively high temperature such as 38 C to 52 C, immediately before use and it is difficult to uniformly distribute the drug in the polymeric composition. U.S. Patent No. 5,612,052 discloses a block copolymer composition that when contacted with water forms a hydrogel.
However, the drug incorporated in this composition is rapidly released. U.S. Patent No.
5,599,552 discloses a composition wherein a water-insoluble biodegradable thermoplastic polymer is dissolved in a water-miscible organic solvent, and the resulting composition can be implanted where it then undergoes a phase transition when in contact with water or body fluids.
However, the drawback is that it is difficult to use because a mono-molecular organic solvent is used to dissolve the biodegradable thermoplastic polymer. Most mono-organic solvents, such as N-methy-2-pyrrolidone, ethyl lactate, dimethylsulfoxide, etc., cause side effects such as cell dehydration and tissue necrosis, etc. and they may also cause severe pain at the application sites.
U.S. Patent No. 5,607,686 discloses a liquid polymeric composition prepared by mixing a hydrophilic liquid polymer, instead of a mono-molecular organic solvent, with a water-insoluble hydrophobic polymer. When contacted with water the composition undergoes a phase transition and forms an implant and thus it does not cause a the rapid volume reduction and it has no special side effects due to the good cyto-compatibility of the low molecular weight
However, the drawback is that it is difficult to use because a mono-molecular organic solvent is used to dissolve the biodegradable thermoplastic polymer. Most mono-organic solvents, such as N-methy-2-pyrrolidone, ethyl lactate, dimethylsulfoxide, etc., cause side effects such as cell dehydration and tissue necrosis, etc. and they may also cause severe pain at the application sites.
U.S. Patent No. 5,607,686 discloses a liquid polymeric composition prepared by mixing a hydrophilic liquid polymer, instead of a mono-molecular organic solvent, with a water-insoluble hydrophobic polymer. When contacted with water the composition undergoes a phase transition and forms an implant and thus it does not cause a the rapid volume reduction and it has no special side effects due to the good cyto-compatibility of the low molecular weight
6 PCT/US2003/016987 polyethylene oxide. However, the water-insoluble hydrophobic polymers used are not biodegradable. In addition, the preparation of the composition requires heating to about 80 C in order to achieve uniform mixing of the water-insoluble hydrophobic polymer and the hydrophilic liquid polymer. Therefore, this system may be suitable to use for adherence 5 prevention and wound protection without any physiologically active substance, but it is not suitable for delivery of physiologically active substances, particularly peptide or protein medicines because peptide and protein medicines lose their activities at high temperatures.
Furthermore, protein medicines are water soluble, thus it is very difficult to uniformly incorporate them into the composition. In addition, it is not disclosed in this patent how the drugs or physiologically active substances can be uniformly incorporated in the polymeric composition. Particularly, although polylactide, polyglycolide and their copolymcrs can be mixed with polyethylene glycol at high teniperatures of 80 C in order to obtain a uniform composition, the composition undergoes phase separation when it stands for a long period of time due the lowered affinity of the polylactide, the polyglycolide or their copolymers with polyethylene glycol. Therefore, it is very difficult to maintain a uniform composition.
Sterilization steps are necessary in the preparation of implant formulations.
Existing sterilization methods are unsuitable for sustained drug delivery formulations due to properties of the implant compositions or because the methods are uneconomical or too complicated. For example, it is almost impossible to prepare a uniform solution by mixing a drug, a water-insoluble biodegradable polymer and a hydrophilic polymer. Therefore, the composition cannot be sterilized by simple methods such as membrane filtration. Furthermore, although the formulation may be prepared under sterilize conditions, such methods are very expensive to the extent that the practicability of the preparation may be lowered.
Therefore, there is a need for a biodegradable drug delivery composition that is a flowable liquid or can be rapidly reconstituted in an aqueous vehicle to afford a homogeneous WO 20041002456 PCT/LiS20031016987 true solution or uniform colloidal system in order to be easily prepared and administered to provide improved drug delivery. Accordingly, the present invention represents improved drug delivery compositions that minimize or are free of the problems mentioned above.
SUMMARY OF THE INVFNTION -The present invention provides biodegradable compositions for drug delivery and is a flowable liquid or can be rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system, and methods of use thereof for preparing a pharmaceutically effective formulation for delivery of drugs.
The present invention also provides a method for preparing the biodegradable drug delivery composition and a method for effectively administering such a composition to warm blooded animals. The drug delivery composition of the present invention can be administered directly to a warm blooded animal without an aqueous vehicle, or can be administered after being rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system. The administration can be done by any functional means such as parenteral, ocular, inhalation, transdermal, vaginal, buccal, transmucosal, transurethral, rectal, nasal, oral, peroral, pulmonary, topical or aural and any other means of administration that may be compatible with the present invention.
The composition of the present invention comprises: 1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block, wherein the A block is a biodegradable polyester or poly(ortho ester) and the B block is polyethylene glycol (PEG) and the weight percentage of the A block is between 20% to 99%; and 2) a polyethylene glycol (PEG), a PEG derivative, or a mixtures of PEG and a PEG derivative, wherein the biodegradable drug carrier is soluble in the liquid PEG. and/or PEG derivatives. The weight averaged molecular weight of the biodegradable block copolymer of the present invention is preferably within the range of 1,000 to 100,000 Daltons, more preferably within the range of 1,000 to
Furthermore, protein medicines are water soluble, thus it is very difficult to uniformly incorporate them into the composition. In addition, it is not disclosed in this patent how the drugs or physiologically active substances can be uniformly incorporated in the polymeric composition. Particularly, although polylactide, polyglycolide and their copolymcrs can be mixed with polyethylene glycol at high teniperatures of 80 C in order to obtain a uniform composition, the composition undergoes phase separation when it stands for a long period of time due the lowered affinity of the polylactide, the polyglycolide or their copolymers with polyethylene glycol. Therefore, it is very difficult to maintain a uniform composition.
Sterilization steps are necessary in the preparation of implant formulations.
Existing sterilization methods are unsuitable for sustained drug delivery formulations due to properties of the implant compositions or because the methods are uneconomical or too complicated. For example, it is almost impossible to prepare a uniform solution by mixing a drug, a water-insoluble biodegradable polymer and a hydrophilic polymer. Therefore, the composition cannot be sterilized by simple methods such as membrane filtration. Furthermore, although the formulation may be prepared under sterilize conditions, such methods are very expensive to the extent that the practicability of the preparation may be lowered.
Therefore, there is a need for a biodegradable drug delivery composition that is a flowable liquid or can be rapidly reconstituted in an aqueous vehicle to afford a homogeneous WO 20041002456 PCT/LiS20031016987 true solution or uniform colloidal system in order to be easily prepared and administered to provide improved drug delivery. Accordingly, the present invention represents improved drug delivery compositions that minimize or are free of the problems mentioned above.
SUMMARY OF THE INVFNTION -The present invention provides biodegradable compositions for drug delivery and is a flowable liquid or can be rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system, and methods of use thereof for preparing a pharmaceutically effective formulation for delivery of drugs.
The present invention also provides a method for preparing the biodegradable drug delivery composition and a method for effectively administering such a composition to warm blooded animals. The drug delivery composition of the present invention can be administered directly to a warm blooded animal without an aqueous vehicle, or can be administered after being rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system. The administration can be done by any functional means such as parenteral, ocular, inhalation, transdermal, vaginal, buccal, transmucosal, transurethral, rectal, nasal, oral, peroral, pulmonary, topical or aural and any other means of administration that may be compatible with the present invention.
The composition of the present invention comprises: 1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block, wherein the A block is a biodegradable polyester or poly(ortho ester) and the B block is polyethylene glycol (PEG) and the weight percentage of the A block is between 20% to 99%; and 2) a polyethylene glycol (PEG), a PEG derivative, or a mixtures of PEG and a PEG derivative, wherein the biodegradable drug carrier is soluble in the liquid PEG. and/or PEG derivatives. The weight averaged molecular weight of the biodegradable block copolymer of the present invention is preferably within the range of 1,000 to 100,000 Daltons, more preferably within the range of 1,000 to
7 50,000 Daltons and most preferably within the range of 1,000 to 15,000 Daltons. Preferably, the weight percentage of the hydrophobic A block in the biodegradable block copolymer is between 20% to 99%, more preferably 20-85%.
In one aspect, the invention relates to a composition comprising: 1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block copolymers having a total weight average molecular weight of 2000 to 4990 Daltons, wherein the A block is a biodegradable polyester or poly (ortho ester) and the B block is polyethylene glycol (PEG), and the weight percentage of the A block is between 51 % to 83% and the weight percentage of the B block is between 17% to 49%; and 2) a polyethylene glycol (PEG), a PEG derivative, or a mixture of PEG and a PEG derivative, said PEG or PEG derivative having a molecular weight of 150 to 1100 Daltons; wherein at least one of the one or more biodegradable block copolymer drug carriers is soluble in an aqueous solution and miscible with the PEG, PEG derivatives, or mixtures thereof;
wherein the weight ratio of the biodegradable block copolymer drug carrier and the PEG, PEG derivative or mixtures thereof is within the range of 5:1 to 1:99 and wherein said composition can be reconstituted in water or an aqueous solution to form a homogeneous solution or a uniform colloidal system within 0.01 minutes to 180 minutes; and wherein the composition possesses reverse thermal gelation properties.
In one aspect, the invention relates to a composition comprising: 1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block copolymers having a total weight average molecular weight of 2000 to 4990 Daltons, wherein the A block is a biodegradable polyester or poly (ortho ester) and the B block is polyethylene glycol (PEG), and the weight percentage of the A block is between 51 % to 83% and the weight percentage of the B block is between 17% to 49%; and 2) a polyethylene glycol (PEG), a PEG derivative, or a mixture of PEG and a PEG derivative, said PEG or PEG derivative having a molecular weight of 150 to 1100 Daltons; wherein at least one of the one or more biodegradable block copolymer drug carriers is soluble in an aqueous solution and miscible with the PEG, PEG derivatives, or mixtures thereof;
wherein the weight ratio of the biodegradable block copolymer drug carrier and the PEG, PEG derivative or mixtures thereof is within the range of 5:1 to 1:99 and wherein said composition can be reconstituted in water or an aqueous solution to form a homogeneous solution or a uniform colloidal system within 0.01 minutes to 180 minutes; and wherein the composition possesses reverse thermal gelation properties.
8 Examples of suitable biodegradable water soluble drug carriers includes biodegradable ABA- or BAB-type triblock copolymers, or AB-type diblock copolymers based on biodegradable polyester or poly(ortho ester) A-blocks and hydrophilic B polymer block(s) consisting of polyethylene glycol (PEG). The biodegradable polyester are synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, E-caprolactone, 1,4-dioxan-2-one, s-hydroxy hexanoic acid, y-butyrolactone, y-hydroxy butyric acid, b-valerolactone, 6-hydroxy valeric acid, hydroxybutyric acids, malic acid, and copolymers thereof.
Polyethylene glycol (PEG) is also sometimes referred to as poly(ethylene oxide) (PEO) or poly(oxyethylene) when incorporated into a block copolymer, and the terms can be used interchangeably for the purposes of this invention.
In the case where the A-block(s) are PLA/PLGA polyester, the lactate content is between about 20 to 100 mole percent, preferably between about 50 to 100 mole percent. The glycolate content is between about 0 and 80 mole percent, preferably between about 0 to 50 mole percent. Or, stated differently, when the A-block is PLGA the glycolate content is between about 1 and 80 mole percent and preferably between about 1 and 50 mole percent and the lactate content is between 20 and 99 mole percent and preferably between 50 and 99 mole percent.
Polyethylene glycol (PEG) is also sometimes referred to as poly(ethylene oxide) (PEO) or poly(oxyethylene) when incorporated into a block copolymer, and the terms can be used interchangeably for the purposes of this invention.
In the case where the A-block(s) are PLA/PLGA polyester, the lactate content is between about 20 to 100 mole percent, preferably between about 50 to 100 mole percent. The glycolate content is between about 0 and 80 mole percent, preferably between about 0 to 50 mole percent. Or, stated differently, when the A-block is PLGA the glycolate content is between about 1 and 80 mole percent and preferably between about 1 and 50 mole percent and the lactate content is between 20 and 99 mole percent and preferably between 50 and 99 mole percent.
9 The PEG derivative suitable in the present invention refers to an ester or ortho ester derivatized PEG having a molecular weight of 150 to 1100. Preferably, the ester derivatized PEG is a PEG derivatized from a member selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, E-caprolactone, 1,4-dioxan-2-one, e-hydroxy hexanoic acid, Y-butyrolactone, y-hydroxy butyric acid, S-valerolactone, S-hydroxy valeric acid, hydroxybutyric acids, malic acid, and mixtures thereof. The PEG derivative can also be a member represented by R'-CO-O-(CHZ-CHZ-O)õ -CO-RZ or R1-O-( CHZ-CH2-O)õ -R2 wherein R' and R2 are independently members selected from the group consisting of H and C, to Cio alkyl and n is an integer between 3 and 20.
The biodegradable block copolymer drug carriers suitable for the present invention can form homogeneous, free-flowing solutions or uniform colloidal systems in an aqueous vehicle or in the liquid PEG or PEG derivatives or mixtures thereof. Homogeneous solutions and uniform colloidal systems of the drug delivery compositiohs includes all flowing forms of the compositions of the present invention, with or without water, drug(s), and any additives or excipients as necessary to prepare formulations that are pharmaceutically and therapeutically useful. The drug may be present as either a true solution or in a colloidal state such as emulsion or a suspension. All forms can act to facilitate administration of the drug and enhance the therapeutic effect. Such therapeutic effects may be optimized by controlling the copolymer molecular weights, compositions, and the relative ratios of the hydrophilic and hydrophobic blocks, ratios of drug to copolymer, ratios of copolymer to PEG and/or PEG
derivatives, and both drug and copolymer concentrations in the final administered dosage form.
Additional advantages of this invention will become apparent from the following detailed description of the various embodiments.
DETAILED DESCRIPTION
This invention is not limited to the particular configurations, process steps, and materials disclosed herein, as such configurations, process steps, and materials may vary somewhat. It is 5 also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.
In this specification and the appended claims, the singular forms "a," "an,"
and "the"
include plural references unless the context clearly dictates otherwise. Thus, for example,
The biodegradable block copolymer drug carriers suitable for the present invention can form homogeneous, free-flowing solutions or uniform colloidal systems in an aqueous vehicle or in the liquid PEG or PEG derivatives or mixtures thereof. Homogeneous solutions and uniform colloidal systems of the drug delivery compositiohs includes all flowing forms of the compositions of the present invention, with or without water, drug(s), and any additives or excipients as necessary to prepare formulations that are pharmaceutically and therapeutically useful. The drug may be present as either a true solution or in a colloidal state such as emulsion or a suspension. All forms can act to facilitate administration of the drug and enhance the therapeutic effect. Such therapeutic effects may be optimized by controlling the copolymer molecular weights, compositions, and the relative ratios of the hydrophilic and hydrophobic blocks, ratios of drug to copolymer, ratios of copolymer to PEG and/or PEG
derivatives, and both drug and copolymer concentrations in the final administered dosage form.
Additional advantages of this invention will become apparent from the following detailed description of the various embodiments.
DETAILED DESCRIPTION
This invention is not limited to the particular configurations, process steps, and materials disclosed herein, as such configurations, process steps, and materials may vary somewhat. It is 5 also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.
In this specification and the appended claims, the singular forms "a," "an,"
and "the"
include plural references unless the context clearly dictates otherwise. Thus, for example,
10 reference to a composition for delivering "a drug" includes reference to one, two, or more drugs.
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
"Effective amount" means an amount of a drug, biologically active agent or pharmacologically active agent that provides the desired local or systemic effect.
"Copolymer solution", when used in reference to a biodegradable block copolymer contained in such a solution, shall mean an aqueous composition having such biodegradable block copolymer drug carrier either dissolved to form a homogeneous solution or uniform colloidal system.
"Drug formulations", "drug delivery compositions", and the like, shall mean the combination of drug, the block copolymer drug carrier, and PEG, PEG
derivatives, or mixtures of PEG and PEG derivatives. They shall include all combinations of the drug with the block copolymer and PEG, PEG derivatives, or mixtures thereof.
"Aqueous solution", "aqueous vehicle" and the like, shall include water without additives or aqueous solutions containing additives or excipients such as pH buffers, components for
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
"Effective amount" means an amount of a drug, biologically active agent or pharmacologically active agent that provides the desired local or systemic effect.
"Copolymer solution", when used in reference to a biodegradable block copolymer contained in such a solution, shall mean an aqueous composition having such biodegradable block copolymer drug carrier either dissolved to form a homogeneous solution or uniform colloidal system.
"Drug formulations", "drug delivery compositions", and the like, shall mean the combination of drug, the block copolymer drug carrier, and PEG, PEG
derivatives, or mixtures of PEG and PEG derivatives. They shall include all combinations of the drug with the block copolymer and PEG, PEG derivatives, or mixtures thereof.
"Aqueous solution", "aqueous vehicle" and the like, shall include water without additives or aqueous solutions containing additives or excipients such as pH buffers, components for
11 tonicity adjustment, antioxidants, preservatives, drug stabilizers, etc., as commonly used in the preparation of phannaceutical forrnulations.
"Drug solution", "solubilized drug", "dissolved drug" and all other terms that refer to the drug in a solution or dissolved state includes the drug being present as either a homogeneous solution, micellar solution, or in a colloidal state such as emulsion or a suspension. Thus, solubilized drugs and drug solutions include all flowing forms of the drug delivery compositions of the present invention. All forms can act to facilitate administration of the drug and enhance the therapeutic effect.
"Reconstitution" refers to mixing of biodegradable block copolymer drug carriers and the PEG, PEG derivatives or mixtures thereof with an aqueous solvent system to create a homogenous solution or uniform colloidal system. This is in addition to the more traditional definition of reconstitution where drug and excipients are mixed with a solvent, usually aqueous, immediately before administration.
"Enhanced reconstitution properties" refers to properties that enable rapid reconstitution of block copolymeric drug carriers to the final physical state as either a true solution or a uniform colloidal system. The reconstitution process occurs within a short period of time, typically between 0.01 minutes to 120 minutes, preferably within 0.01 minutes to 60 minutes, and most preferably within 0.01 minutes to 30 minutes.
"Reverse thermal gelation" is the phenomenon whereby an aqueous solution of a block copolymer spontaneously increases in viscosity, and in many instances transforms into a semisolid gel, as the temperature of the polymer solution is increased above the gelation temperature of the block copolymer solution. For the purpose of the invention, the term gel includes both the semisolid gel state and the high viscosity state that exists above the gelation temperature. When cooled below the gelation temperature the gel spontaneously
"Drug solution", "solubilized drug", "dissolved drug" and all other terms that refer to the drug in a solution or dissolved state includes the drug being present as either a homogeneous solution, micellar solution, or in a colloidal state such as emulsion or a suspension. Thus, solubilized drugs and drug solutions include all flowing forms of the drug delivery compositions of the present invention. All forms can act to facilitate administration of the drug and enhance the therapeutic effect.
"Reconstitution" refers to mixing of biodegradable block copolymer drug carriers and the PEG, PEG derivatives or mixtures thereof with an aqueous solvent system to create a homogenous solution or uniform colloidal system. This is in addition to the more traditional definition of reconstitution where drug and excipients are mixed with a solvent, usually aqueous, immediately before administration.
"Enhanced reconstitution properties" refers to properties that enable rapid reconstitution of block copolymeric drug carriers to the final physical state as either a true solution or a uniform colloidal system. The reconstitution process occurs within a short period of time, typically between 0.01 minutes to 120 minutes, preferably within 0.01 minutes to 60 minutes, and most preferably within 0.01 minutes to 30 minutes.
"Reverse thermal gelation" is the phenomenon whereby an aqueous solution of a block copolymer spontaneously increases in viscosity, and in many instances transforms into a semisolid gel, as the temperature of the polymer solution is increased above the gelation temperature of the block copolymer solution. For the purpose of the invention, the term gel includes both the semisolid gel state and the high viscosity state that exists above the gelation temperature. When cooled below the gelation temperature the gel spontaneously
12 reverses to reform the lower viscosity polymer solution. This cycling between the solution and the gel may be repeated indefinitely because the sot/gel transition does not involve any change in the chemical composition of the polymer solution. All interactions to create the gel are physical in nature and do not involve the formation or breaking of covalent bonds.
"Administration" is the means by which drug formulations are presented to humans and other warrn-blooded animals in effective amounts, and includes all routes for dosing or administering drugs, whether self-administered or administered by medical practitioners.
"Parenteral" shall mean administration by means other than through the digestive tract such as by intramuscular, intraperitoneal, intra abdominal, subcutaneous, intrathecal, intrapleural, intravenous and intraarterial means.
"Depot" means a localized site in the body containing concentrated active agents or drugs. Examples of formulations that form depots are gels, implants, microspheres, matrices, particles, etc.
"Biodegradable" means that the block copolymer or oligomer can chemically break down or degrade within the body to fornl nontoxic components. The rate of degradation can be the same or different from the rate of drug release.
"Drug" shall mean any organic or inorganic compound or substance having biological or pharmacological activity that can be adapted or used for a therapeutic purpose.
"Peptide," "polypeptide," "oligopeptide" and "protein" shall be used interchangeably when referring to peptide or protein drugs and shall not be limited as to any particular molecular weight, peptide sequence or length, field of bioactivity or therapeutic use unless specifically stated.
"PLGA" shall mean a copolymer or copolymer radicals derived from the condensation copolymerization of lactic acid and glycolic acid, or, by the ring opening copolymerization of WO 20041002156 PCT/US2003H)16987
"Administration" is the means by which drug formulations are presented to humans and other warrn-blooded animals in effective amounts, and includes all routes for dosing or administering drugs, whether self-administered or administered by medical practitioners.
"Parenteral" shall mean administration by means other than through the digestive tract such as by intramuscular, intraperitoneal, intra abdominal, subcutaneous, intrathecal, intrapleural, intravenous and intraarterial means.
"Depot" means a localized site in the body containing concentrated active agents or drugs. Examples of formulations that form depots are gels, implants, microspheres, matrices, particles, etc.
"Biodegradable" means that the block copolymer or oligomer can chemically break down or degrade within the body to fornl nontoxic components. The rate of degradation can be the same or different from the rate of drug release.
"Drug" shall mean any organic or inorganic compound or substance having biological or pharmacological activity that can be adapted or used for a therapeutic purpose.
"Peptide," "polypeptide," "oligopeptide" and "protein" shall be used interchangeably when referring to peptide or protein drugs and shall not be limited as to any particular molecular weight, peptide sequence or length, field of bioactivity or therapeutic use unless specifically stated.
"PLGA" shall mean a copolymer or copolymer radicals derived from the condensation copolymerization of lactic acid and glycolic acid, or, by the ring opening copolymerization of WO 20041002156 PCT/US2003H)16987
13 lactide and glycolide. The tenns lactic acid and lactate are used interchangeably; glycolic acid and glycolate are also used interchangeably.
"PLA" shall mean a polymer derived from the condensation of lactic acid or by the ring opening polymerization of lactide.
"PGA" shall mean a polymer derived from the condensation of glycolic acid or by the ring opening polymerization of glycolide.
"Biodegradable polyester or poly(ortho ester)s" refers to any biodegradable polyester or poly(ortho ester)s. The polyesters are preferably synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, s-caprolactone, 1,4-dioxan-2-one, -hydroxy hexanoic acid, Y-butyrolactone, y-hydroxy butyric acid, S-valerolactone, S-hydroxy valeric acid, hydroxybutyric acid, malic acid, and mixtures thereof.
"Ortho ester" is a carbon which single bonded to three oxygen atoms covalently.
The present invention is based on the discovery of PEG, PEG derivatives or mixtures thereof that can, in minutes, efficiently accelerate the dissolution of the biodegradable block copolymer drug carriers into an aqueous medium. The liquid PEG, PEG
derivatives or mixtures thereof of the present invention can also dissolve the biodegradable block copolymer drug carriers to create a flowable drug delivery composition. The "PEG, PEG
derivatives or mixtures thereof' of the present invention have a weight averaged molecular weight of 150 to 1100. The PEG derivative suitable in the present invention refers to an ester or ortho ester derivatized PEG
having a molecular weight of 150 to 1100. Preferably, the ester derivatized PEG is a PEG
derivatized from a member selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, E-caprolactone, 1,4-dioxan-2-one, E-hydroxy hexanoic acid, 1-butyrolactone, y-hydroxy butyric acid, S-
"PLA" shall mean a polymer derived from the condensation of lactic acid or by the ring opening polymerization of lactide.
"PGA" shall mean a polymer derived from the condensation of glycolic acid or by the ring opening polymerization of glycolide.
"Biodegradable polyester or poly(ortho ester)s" refers to any biodegradable polyester or poly(ortho ester)s. The polyesters are preferably synthesized from monomers selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, s-caprolactone, 1,4-dioxan-2-one, -hydroxy hexanoic acid, Y-butyrolactone, y-hydroxy butyric acid, S-valerolactone, S-hydroxy valeric acid, hydroxybutyric acid, malic acid, and mixtures thereof.
"Ortho ester" is a carbon which single bonded to three oxygen atoms covalently.
The present invention is based on the discovery of PEG, PEG derivatives or mixtures thereof that can, in minutes, efficiently accelerate the dissolution of the biodegradable block copolymer drug carriers into an aqueous medium. The liquid PEG, PEG
derivatives or mixtures thereof of the present invention can also dissolve the biodegradable block copolymer drug carriers to create a flowable drug delivery composition. The "PEG, PEG
derivatives or mixtures thereof' of the present invention have a weight averaged molecular weight of 150 to 1100. The PEG derivative suitable in the present invention refers to an ester or ortho ester derivatized PEG
having a molecular weight of 150 to 1100. Preferably, the ester derivatized PEG is a PEG
derivatized from a member selected from the group consisting of D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, E-caprolactone, 1,4-dioxan-2-one, E-hydroxy hexanoic acid, 1-butyrolactone, y-hydroxy butyric acid, S-
14 valerolactone, S-hydroxy valeric acid, hydroxybutyric acids, malic acid, and mixtures thereof.
The PEG derivative can also be a member represented by RI-CO-O-(CHZ-CH2-O),;
CO-RZ or RI-O-(CH2-CH2-O)n R2 wherein R' and R2 are independently members selected from the group consisting of H and C 1 to C1a alkyl and n is an integer between 3 and 20.
The biodegradable block copolymer drug carriers of the present invention may be soluble in an aqueous solution, in the liquid PEG, PEG derivatives or mixtures thereof, or both.
Examples of some of these biodegradable block copolymer drug carriers are disclosed in U.S.
Patent 6,201,072 and pending U.S. patent applications, Serial Nos. 09/559,799;
09/971,074, filed on 10/03/2001 and 09/971,082 filed on 10/03/2001, hereby fully incorporated by reference.
The composition can be administered as is or after being dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system.
After the administration, the water soluble biodegradable block copolymer may or may not form a gel, depending on molecular weight and hydrophobic block weight percentage of the block copolymer contained in the composition. Water soluble biodegradable block copolymers are prepared wherein the hydrophilic B-block(s) make up about 17 to 49.9% by weight of the copolymer and the hydrophobic A-block or blocks make up about 50.1 to 83% by weight of the copolymer. The weight ratio of the water soluble biodegradable block copolymer drug carrier and the PEG, PEG derivatives, or mixtures of PEG and PEG derivatives, is between 5:1 and 1:99. This composition can be administered as is or after being quickly reconstituted in water or an aqueous solution and form a polymer solution comprising the composition of the present invention in water or the aqueous solution at a weight ratio between 2:1 and 1:10000.
Alternatively, the biodegradable block copolymer may be insoluble in an aqueous solution but is soluble in the liquid polyethylene glycol, PEG derivatives or mixtures thereof. In this case, the liquid composition is a homogeneous solution or uniform colloidal system and can be administered directly to a warm blooded animal. After the administration, the liquid composition forms a drug containing depot and slowly releases the active substance over a prolonged period of time and is then decomposed into materials harmless to the human body and excreted. In the liquid composition of the present invention, the weight ratio of the biodegradable block copolymer to the PEG, PEG derivatives or mixtures thereof is preferably 5 within the range of 5:1 to 1:99, and more preferably within the range of 2:1 to 1:99 and most preferably within the range of 1:2 to 1:5.
In one embodiment, the biodegradable drug carrier comprises ABA-type or BAB-type triblock copolymers, AB-type diblock copolymers or mixtures thereof, where the A-blocks are relatively hydrophobic and comprises a biodegradable polyester or poly(ortho ester), and 10 the B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG), said copolymer having a hydrophobic content of between 50.1 to 83% by weight and hydrophilic content of between 17 to 49.9% by weight, and an overall block copolymer molecular weight of between 2000 and 8000. The drug carriers exhibit water solubility at temperatures below normal mammalian body temperatures and undergoes reversible thermal gelation to
The PEG derivative can also be a member represented by RI-CO-O-(CHZ-CH2-O),;
CO-RZ or RI-O-(CH2-CH2-O)n R2 wherein R' and R2 are independently members selected from the group consisting of H and C 1 to C1a alkyl and n is an integer between 3 and 20.
The biodegradable block copolymer drug carriers of the present invention may be soluble in an aqueous solution, in the liquid PEG, PEG derivatives or mixtures thereof, or both.
Examples of some of these biodegradable block copolymer drug carriers are disclosed in U.S.
Patent 6,201,072 and pending U.S. patent applications, Serial Nos. 09/559,799;
09/971,074, filed on 10/03/2001 and 09/971,082 filed on 10/03/2001, hereby fully incorporated by reference.
The composition can be administered as is or after being dissolved or rapidly reconstituted in an aqueous vehicle to afford a homogeneous solution or uniform colloidal system.
After the administration, the water soluble biodegradable block copolymer may or may not form a gel, depending on molecular weight and hydrophobic block weight percentage of the block copolymer contained in the composition. Water soluble biodegradable block copolymers are prepared wherein the hydrophilic B-block(s) make up about 17 to 49.9% by weight of the copolymer and the hydrophobic A-block or blocks make up about 50.1 to 83% by weight of the copolymer. The weight ratio of the water soluble biodegradable block copolymer drug carrier and the PEG, PEG derivatives, or mixtures of PEG and PEG derivatives, is between 5:1 and 1:99. This composition can be administered as is or after being quickly reconstituted in water or an aqueous solution and form a polymer solution comprising the composition of the present invention in water or the aqueous solution at a weight ratio between 2:1 and 1:10000.
Alternatively, the biodegradable block copolymer may be insoluble in an aqueous solution but is soluble in the liquid polyethylene glycol, PEG derivatives or mixtures thereof. In this case, the liquid composition is a homogeneous solution or uniform colloidal system and can be administered directly to a warm blooded animal. After the administration, the liquid composition forms a drug containing depot and slowly releases the active substance over a prolonged period of time and is then decomposed into materials harmless to the human body and excreted. In the liquid composition of the present invention, the weight ratio of the biodegradable block copolymer to the PEG, PEG derivatives or mixtures thereof is preferably 5 within the range of 5:1 to 1:99, and more preferably within the range of 2:1 to 1:99 and most preferably within the range of 1:2 to 1:5.
In one embodiment, the biodegradable drug carrier comprises ABA-type or BAB-type triblock copolymers, AB-type diblock copolymers or mixtures thereof, where the A-blocks are relatively hydrophobic and comprises a biodegradable polyester or poly(ortho ester), and 10 the B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG), said copolymer having a hydrophobic content of between 50.1 to 83% by weight and hydrophilic content of between 17 to 49.9% by weight, and an overall block copolymer molecular weight of between 2000 and 8000. The drug carriers exhibit water solubility at temperatures below normal mammalian body temperatures and undergoes reversible thermal gelation to
15 then exist as a gel at temperatures equal to physiological mammalian body temperatures.
In another embodiment, the biodegradable drug carrier is an ABA-type, BAB-type, or AB-type block copolymer, or mixtures thereof, where the A-blocks are relatively hydrophobic and comprises a biodegradable polyester or poly(ortho ester), and the B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG), said block copolymer having a hydrophobic content of between 50.1 to 65% by weight and a hydrophilic content of between 35 to 49.9% by weight, and an overall block copolymer weight-averaged molecular weight of between 2400 and 4999. The drug carriers are water soluble and capable of enhancing the solubility of drugs, hydrophobic drugs in particular, in water, to forrn a drug solution.
WO 2004/0024ui PCT/US2003/016987
In another embodiment, the biodegradable drug carrier is an ABA-type, BAB-type, or AB-type block copolymer, or mixtures thereof, where the A-blocks are relatively hydrophobic and comprises a biodegradable polyester or poly(ortho ester), and the B-blocks are relatively hydrophilic and comprises polyethylene glycol (PEG), said block copolymer having a hydrophobic content of between 50.1 to 65% by weight and a hydrophilic content of between 35 to 49.9% by weight, and an overall block copolymer weight-averaged molecular weight of between 2400 and 4999. The drug carriers are water soluble and capable of enhancing the solubility of drugs, hydrophobic drugs in particular, in water, to forrn a drug solution.
WO 2004/0024ui PCT/US2003/016987
- 16 In still another embodiment, the polymeric drug carrier comprises biodegradable polyester or poly(ortho ester) oligomers, and particularly PLA/PLGA oligomers having a weight averaged molecular weight of between 400 and 10,000, mixed with biodegradable ABA-type or BAB-type triblock copolymers, or AB-type diblock copolymers having a weight averaged molecular weight of between 2400 and 4999. The block copolymers have 50.1 to 65% by weight of the hydrophobic A block(s) comprising biodegradable polyester or poly(ortho ester)s and 35 to 49.9% by weight of the hydrophilic B block(s) consisting of polyethylene glycol (PEG).
The PEG, PEG derivatives or mixtures thereof used in the present invention dissolves or uniformly mixes with the biodegradable block copolymer and so reduces the viscosity and increases the fluidity of the composition. The compositions of the present invention are flowable liquids or can be easily formulated with an aqueous vehicle to afford a fluid homogeneous solution or uniform colloidal system. In the cases that the block copolymeric drug carrier is insoluble in an aqueous vehicle but soluble in the liquid PEG
and/or PEG derivatives, when in contact with water or body fluids, the block copolymer forms a drug depot. In cases that the block copolymeric drug carrier is soluble in an aqueous vehicle and miscible with the PEG and/or PEG derivatives, the composition can be easily administered as is or reconstituted with an aqueous vehicle. After the administration, the block copolymer drug carrier may or may not form a'drug depot. Therefore, the liquid PEG, PEG derivative or mixtures thereof of the present invention should be a material that does not cause loss of activity of the physiologically active substance.
For purposes of disclosing molecular weight parameters, all reported molecular weight values are based on measurements by 'H-NMR or GPC (gel permeation chromatography) analytical techniques. The reported weight averaged molecular weights and number averaged molecular weights were determined by GPC and 'H-NMR, respectively. The reported . . . . ... . . . .~ . .. ... . .. . . . . . .. _... . _. . _.. . .. . ....
... .. . .
The PEG, PEG derivatives or mixtures thereof used in the present invention dissolves or uniformly mixes with the biodegradable block copolymer and so reduces the viscosity and increases the fluidity of the composition. The compositions of the present invention are flowable liquids or can be easily formulated with an aqueous vehicle to afford a fluid homogeneous solution or uniform colloidal system. In the cases that the block copolymeric drug carrier is insoluble in an aqueous vehicle but soluble in the liquid PEG
and/or PEG derivatives, when in contact with water or body fluids, the block copolymer forms a drug depot. In cases that the block copolymeric drug carrier is soluble in an aqueous vehicle and miscible with the PEG and/or PEG derivatives, the composition can be easily administered as is or reconstituted with an aqueous vehicle. After the administration, the block copolymer drug carrier may or may not form a'drug depot. Therefore, the liquid PEG, PEG derivative or mixtures thereof of the present invention should be a material that does not cause loss of activity of the physiologically active substance.
For purposes of disclosing molecular weight parameters, all reported molecular weight values are based on measurements by 'H-NMR or GPC (gel permeation chromatography) analytical techniques. The reported weight averaged molecular weights and number averaged molecular weights were determined by GPC and 'H-NMR, respectively. The reported . . . . ... . . . .~ . .. ... . .. . . . . . .. _... . _. . _.. . .. . ....
... .. . .
17 lactidelglycolide ratios were calculated from 'H-NMR data. GPC analysis was performed on a Styragel HR-3 column, or equivalent, calibrated with PEG standards using RI
detection and chloroform as the eluent, or on a combination of Phenogel, mixed bed, and 500 A colunms calibrated with PEG standards using RI detection and tetrahydrofuran as the eluent for the ABA
and BAB triblock copolymers.
ABA-type and BAB-type triblock copolymers, and AB-type diblock copolymers may be synthesized by ring opening polymerization, or condensation polymerization.
Additionally, the B-blocks may, in certain instances, be coupled to the A-blocks by ester or urethane links and the like. Condensation polymerization and ring opening polymerization procedures may be utilized as may the coupling of a monofunctional hydrophilic B block to either end of a difunctional hydrophobic A block in the presence of coupling agents such as isocyanates.
Furthermore, coupling reactions may follow activation of functional groups with activating agents, such as carbonyl diimidazole, succinic anhydride, N-hydroxy succinimide, p-nitrophenyl chloroformate and the like.
'I'he hydrophilic B-block is formed from PEG of an appropriate molecular weight. PEG was chosen as the hydrophilic B-block because of its unique biocompatibility, nontoxic properties, hydrophilicity, solubilization properties, and rapid clearance from a patient's body. The hydrophobic A-blocks are utilized because of their biodegradable, biocompatible, and solubilization properties. The in vitro and in vivo degradation of hydrophobic, biodegradable polyester or poly(ortho ester) A-blocks are well understood and the degradation products are readily metabolized and/or eliminated from the patient's body.
Drugs that may be incorporated with the drug delivery compositions of the present invention can be any bioactive agent, but particular advantage is achieved with bioactive agents having limited solubility or dispersibility in an aqueous or hydrophilic environment, or any bioactive agent that requires enhanced solubility or dispersibility. Without limiting the scope of
detection and chloroform as the eluent, or on a combination of Phenogel, mixed bed, and 500 A colunms calibrated with PEG standards using RI detection and tetrahydrofuran as the eluent for the ABA
and BAB triblock copolymers.
ABA-type and BAB-type triblock copolymers, and AB-type diblock copolymers may be synthesized by ring opening polymerization, or condensation polymerization.
Additionally, the B-blocks may, in certain instances, be coupled to the A-blocks by ester or urethane links and the like. Condensation polymerization and ring opening polymerization procedures may be utilized as may the coupling of a monofunctional hydrophilic B block to either end of a difunctional hydrophobic A block in the presence of coupling agents such as isocyanates.
Furthermore, coupling reactions may follow activation of functional groups with activating agents, such as carbonyl diimidazole, succinic anhydride, N-hydroxy succinimide, p-nitrophenyl chloroformate and the like.
'I'he hydrophilic B-block is formed from PEG of an appropriate molecular weight. PEG was chosen as the hydrophilic B-block because of its unique biocompatibility, nontoxic properties, hydrophilicity, solubilization properties, and rapid clearance from a patient's body. The hydrophobic A-blocks are utilized because of their biodegradable, biocompatible, and solubilization properties. The in vitro and in vivo degradation of hydrophobic, biodegradable polyester or poly(ortho ester) A-blocks are well understood and the degradation products are readily metabolized and/or eliminated from the patient's body.
Drugs that may be incorporated with the drug delivery compositions of the present invention can be any bioactive agent, but particular advantage is achieved with bioactive agents having limited solubility or dispersibility in an aqueous or hydrophilic environment, or any bioactive agent that requires enhanced solubility or dispersibility. Without limiting the scope of
18 the present invention, suitable drugs include those drugs presented in current edition of Goodman and Gilman's "The Pharmacological Basis of Therapeutics" or the current edition of The Merck Index. Both volumes list drugs suitable for numerous types of therapeutic applications, including drugs in the following categories:drugs acting at synaptic and neuroeffector junctional sites, drugs acting on the central nervous system, drugs that influence inflammatory responses, drugs that affect the composition of body fluids, drugs affecting renal function and electrolyte metabolism, cardiovascular drugs, drugs affecting gastrointestinal function, drugs affecting uterine motility, chemotherapeutic agents for parasitic infections, chemotherapeutic agents for microbial diseases, antineoplastic agents, immunosuppressive agents, drugs affecting the blood and blood-forming organs, hormones and hormone antagonists, dermatological agents, heavy metal antagonists, vitamins and nutrients, vaccines, oligonucleotides and gene therapies.
Incorporating one or more drugs mentioned in the above categories with the compositions of the present invention to form drug delivery compositions which can be dissolved or easily reconstituted to fonn an aqueous solution or uniform colloidal system can be achieved by simply adding the drug to the liquid composition or an aqueous solutions of the compositions of the present invention, or by mixing the drug with the compositions of the present invention and thereafter adding water or an aqueous solution to form a solution or uniform colloidal system.
Mixtures of the compositions of the present invention with peptidelprotein drugs, and/or other types of drugs, may be prepared as flowable drug delivery formulations or formulations that may be easily reconstituted in the form of a solution or dispersion. The flowable formulation is then administered parenterally, topically, transdermally, transmucosally, inhaled, or inserted into a cavity sucli as by ocular, vaginal, transurethral, rectal, nasal, oral, peroral, buccal, pulmonary or aural administration to a patient. Many of the solubilized drug
Incorporating one or more drugs mentioned in the above categories with the compositions of the present invention to form drug delivery compositions which can be dissolved or easily reconstituted to fonn an aqueous solution or uniform colloidal system can be achieved by simply adding the drug to the liquid composition or an aqueous solutions of the compositions of the present invention, or by mixing the drug with the compositions of the present invention and thereafter adding water or an aqueous solution to form a solution or uniform colloidal system.
Mixtures of the compositions of the present invention with peptidelprotein drugs, and/or other types of drugs, may be prepared as flowable drug delivery formulations or formulations that may be easily reconstituted in the form of a solution or dispersion. The flowable formulation is then administered parenterally, topically, transdermally, transmucosally, inhaled, or inserted into a cavity sucli as by ocular, vaginal, transurethral, rectal, nasal, oral, peroral, buccal, pulmonary or aural administration to a patient. Many of the solubilized drug
19 formulations prepared by implementing the present invention may be diluted in an i.v. bag or by other means, and administered to a patient for an extended period, without precipitation of the drug. Due to the biocompatibility of the materials and the free flowing nature of the system at physiological temperatures, this system will cause minimal toxicity and minimal mechanical irritation to the surrounding tissue.
A distinct advantage to the compositions of this invention lies in the ability of PEG, PEG
derivatives or mixtures thereof to reduce the viscosity of the biodegradable block copolymer drug carriers into a forni that is flowable liquid or can be quickly reconstitutable in water or an aqueous solution to form a solution or uniform colloidal system for drug delivery. In one possible configuration, a dosage form comprised of a solution of the block copolymcr drug camer and a PEG, PEG derivatives or mixtures thereof that contains drug is administered to the body. In another possible configuration, the drug delivery composition of the present invention may be quickly dissolved or reconstituted by using water or other aqueous solutions.
The only limitation as to how much drug can be dissolved or dispersed in the drug delivery composition of the present invention is one of functionality, namely, the drug:copolymer ratio may be increased until the properties of the mixture are adversely affected to an unacceptable degree, or until the properties of the system are adversely affected to such a degree as to make administration of the system unacceptably difficult.
Generally speaking, it is anticipated that in most instances where dissolution is desired, the drug will be present at between about l0-6 to about 100 percent by weight of the combined weight the block copolymer drug carrier and the PEG, PEG derivatives or mixtures thereof, with ranges of between about 0.001% to 25% by weight being the most common. For example, having the drug present at 100% by weight of the combined weight of the block copolymer drug carrier and the PEG, PEG
derivatives or mixtures thereof means that the drug and combined weight the block copolymer drug carrier and the PEG, PEG derivatives or mixtures thereof are present in equal amounts (i.e., equal weights). Generally speaking, it is anticipated that in most instances where dispersion is desired, the upper drug:copolymer ratio could substantially exceed the range noted above for dissolution. These ranges of drug loading are illustrative and will include most drugs that may be utilized in the present invention. However, such ranges are not limiting to the invention 5 should drug loadings outside this range be functional and effective.
The present invention thus provides compositions comprising biodegradable block copolymer drug carriers and PEG, PEG derivatives or mixtures thereof that are flowable liquids or can be rapidly reconstituted in an aqueous vehicle to afford useful forms that may be either homogeneous true solutions or uniform colloidal systems. The drug solution formed with the 10 drug delivery compositions of the present invention has desirable physical stability, therapeutic efficacy, and toxicology. The PEG, PEG derivatives or mixtures thereof of the present invention can be used for water soluble or water insoluble block copolymeric drug carriers, particularly for biodegradable di- or triblock copolymers that have reverse gelation properties and/or polymers that can enhance the solubility of drugs, especially hydrophobic drugs. -15 The following are examples that illustrate preferred embodiments of the invention but are intended as being representative only.
Example 1 PEG-300 (107.6 g) was placed in a 250-mL round bottom flask and dried under vacuum
A distinct advantage to the compositions of this invention lies in the ability of PEG, PEG
derivatives or mixtures thereof to reduce the viscosity of the biodegradable block copolymer drug carriers into a forni that is flowable liquid or can be quickly reconstitutable in water or an aqueous solution to form a solution or uniform colloidal system for drug delivery. In one possible configuration, a dosage form comprised of a solution of the block copolymcr drug camer and a PEG, PEG derivatives or mixtures thereof that contains drug is administered to the body. In another possible configuration, the drug delivery composition of the present invention may be quickly dissolved or reconstituted by using water or other aqueous solutions.
The only limitation as to how much drug can be dissolved or dispersed in the drug delivery composition of the present invention is one of functionality, namely, the drug:copolymer ratio may be increased until the properties of the mixture are adversely affected to an unacceptable degree, or until the properties of the system are adversely affected to such a degree as to make administration of the system unacceptably difficult.
Generally speaking, it is anticipated that in most instances where dissolution is desired, the drug will be present at between about l0-6 to about 100 percent by weight of the combined weight the block copolymer drug carrier and the PEG, PEG derivatives or mixtures thereof, with ranges of between about 0.001% to 25% by weight being the most common. For example, having the drug present at 100% by weight of the combined weight of the block copolymer drug carrier and the PEG, PEG
derivatives or mixtures thereof means that the drug and combined weight the block copolymer drug carrier and the PEG, PEG derivatives or mixtures thereof are present in equal amounts (i.e., equal weights). Generally speaking, it is anticipated that in most instances where dispersion is desired, the upper drug:copolymer ratio could substantially exceed the range noted above for dissolution. These ranges of drug loading are illustrative and will include most drugs that may be utilized in the present invention. However, such ranges are not limiting to the invention 5 should drug loadings outside this range be functional and effective.
The present invention thus provides compositions comprising biodegradable block copolymer drug carriers and PEG, PEG derivatives or mixtures thereof that are flowable liquids or can be rapidly reconstituted in an aqueous vehicle to afford useful forms that may be either homogeneous true solutions or uniform colloidal systems. The drug solution formed with the 10 drug delivery compositions of the present invention has desirable physical stability, therapeutic efficacy, and toxicology. The PEG, PEG derivatives or mixtures thereof of the present invention can be used for water soluble or water insoluble block copolymeric drug carriers, particularly for biodegradable di- or triblock copolymers that have reverse gelation properties and/or polymers that can enhance the solubility of drugs, especially hydrophobic drugs. -15 The following are examples that illustrate preferred embodiments of the invention but are intended as being representative only.
Example 1 PEG-300 (107.6 g) was placed in a 250-mL round bottom flask and dried under vacuum
20 (0.2 torr, 90 C) for 3 hours. D,L-Lactide (33.4 g) and glycolide (9.0 g) was added and the head-space was replaced by dried nitrogen. The mixture was brought to 135 C and the reaction was initiated by adding stannous octoate (20 mg) via a dry syringe. The reaction mixture was allowed to stir under dry nitrogen at 155 C for four additional hours.
Residual monomers were removed under vacuum (0.2 torr, 90 C, 2 hr). The resulting PEG derivative(D1) was a clear free-flowing liquid.
Residual monomers were removed under vacuum (0.2 torr, 90 C, 2 hr). The resulting PEG derivative(D1) was a clear free-flowing liquid.
21 Example 2 Following the procedure described in Example 1, the following PEG derivatives were prepared.
Table 1 PEG derivatives synthesized by the method described in Example l ID PEG PEG weight Glycolide D,L-Lactide (gram) am (gram) PEG200NF 30.0 7.62 28.38 PEG200NF 33.33 5.64 21.02 PEG300NF 57.14 4.84 18.02 PEG600NF 50.0 4.23 15.75 Triethylene 50.0 4.23 15.77 D6 glycol PEG300NF 50.25 19.75 -PEG300NF 86.15 24.67 9.19 PEG300NF 100.5 - 39.5 Example 3 PEG-300 (40 g) was placed in a 250-mL round bottom flask. Moisture was removed by drying under vacuum (0.2 torr) at 90 C for 3 hours. Acetic anhydride (30 g) was added and the reaction mixture was brought to reflux under nitrogen over 48 hours. Excess acetic anhydride was renioved by vacuum distillation at 100 C for 24 hours. The resulting PEG
derivative(Di0) was a clear, free-flowing liquid.
Example 4 This example illustrates the synthesis of the ABA-type triblock copolymer PLGA-PEG-PLGA by ring opening copolymerization.
WO 2004/002456 PCTiUS2003/016987
Table 1 PEG derivatives synthesized by the method described in Example l ID PEG PEG weight Glycolide D,L-Lactide (gram) am (gram) PEG200NF 30.0 7.62 28.38 PEG200NF 33.33 5.64 21.02 PEG300NF 57.14 4.84 18.02 PEG600NF 50.0 4.23 15.75 Triethylene 50.0 4.23 15.77 D6 glycol PEG300NF 50.25 19.75 -PEG300NF 86.15 24.67 9.19 PEG300NF 100.5 - 39.5 Example 3 PEG-300 (40 g) was placed in a 250-mL round bottom flask. Moisture was removed by drying under vacuum (0.2 torr) at 90 C for 3 hours. Acetic anhydride (30 g) was added and the reaction mixture was brought to reflux under nitrogen over 48 hours. Excess acetic anhydride was renioved by vacuum distillation at 100 C for 24 hours. The resulting PEG
derivative(Di0) was a clear, free-flowing liquid.
Example 4 This example illustrates the synthesis of the ABA-type triblock copolymer PLGA-PEG-PLGA by ring opening copolymerization.
WO 2004/002456 PCTiUS2003/016987
22 PEG 1000 NF (65.3 g) and PEG 1450 NF (261 g) was dried under vacuum (1 mmHg) at 130 C for 5 hours. D, L-Lactide (531.12 g) and glycolide (142.6 g) were added to the flask and heated to 155 C to afford a homogenous solution. Polymerization was initiated by the addition of 250 mg stannous octoate to the reaction mixture. After maintaining the reaction for five hours at 145 C, the reaction was stopped and the flask was cooled to room temperature.
Unreacted lactide and glycolide were removed by vacuum distillation. The resulting PLGA-PEG-PLGA copolymer mixture(ABA 1) had a weight averaged molecular weight (Mw) of 4255 as measured by GPC. This triblock copolymer mixture is water soluble at room temperature. A
Unreacted lactide and glycolide were removed by vacuum distillation. The resulting PLGA-PEG-PLGA copolymer mixture(ABA 1) had a weight averaged molecular weight (Mw) of 4255 as measured by GPC. This triblock copolymer mixture is water soluble at room temperature. A
23% by weight aqueous solution of this triblock copolymer nlixture had a gel temperature between 30 C and 37 C.
Example 5 Using the procedure described in Example 4, the following copolymers or copolymer mixtures were synthesized:
Table 2 Copolymers synthesized using the procedure described in Example 3 Block LA/GA PEG PEG PEG1/PE MW (Dalton) Remarks Copolymer Molar 1 2 G2 wt Ratio MW MW Ratio PLG-PEG- 75/25 1000 - 100/0 4250 Water PLG soluble ABA 2) PLG-PEG- 75/25 1450 - 100/0 3950 Water PLG soluble (ABA 3 PLA-PEG- 100/0 1000 1450 10/90 3980 Water PLA soluble (ABA 4 PLG-PEG- 75/25 1450 - 100/0 7540 Water PLG insoluble n (ABA 5 PLA-PE- 100/0 1000 600 80/20 6500 Water PLA insoluble ABA 6) 4 _ Example 6 AB diblock copolymer was synthesized by placing 25.7 g of PEG-Me (Mw: 2000) in a 250 mL 3-neck round bottom reaction flask. Water was removed by heating in an oil bath (155 C) under vacuum (0.5 torr) for 3 hours. The reaction flask was then raised out of the oil bath and the vacuum was released.
D,L-Lactide (32.0 g) was weighed and added to the reaction flask. The headspace was replaced with dry nitrogen by repeated evacuation and flushing with dry nitrogen 5 times.
The flask was then lowered and immersed in a 155 C oil bath. Once the content was melted and the intemal temperature reached 150 C, 2 drops (200 ppm) of stannous 2-ethylhexanoate was added to initiate the polymerization. The reaction mixture was stirred using an overhead stirrer for 8 hours at a rate of 100-200 rpm. The temperature was then reduced to 140 C, and the residual monomer was removed under reduced pressure (<1 torr) over 1 hour.
The residue is a translucent, off=white solid having a molecular weight of 5450.
One gram of the diblock copolymer was added to 4 grams of PEG derivative (D
10) to afford a clear and free flowing liquid. Upon addition of the mixture to 37 C
water, the mixture turned cloudy due to apparent precipitation of the water insoluble diblock copolymeric component.
Example 7 Me-PEG (MW 550; 48.6 g) was transferred into a 250 mL 3-neck round bottom reaction flask. The oil bath was heated to 100 C. The molten PEG-Me was stirred under vacuum for 5 hours to remove water. The reaction flask was then raised outside of the oil bath and the vacuum was released. D,L-Lactide (97.68 g) and glycolide (26.47 g) were weighed and added the reaction flask. The headspace was replaced with dry nitrogen. The flask was then immersed . . ........ i . , ... .... . . .. .. . . .. ... ..... ........ ... .. ... ...
.
Example 5 Using the procedure described in Example 4, the following copolymers or copolymer mixtures were synthesized:
Table 2 Copolymers synthesized using the procedure described in Example 3 Block LA/GA PEG PEG PEG1/PE MW (Dalton) Remarks Copolymer Molar 1 2 G2 wt Ratio MW MW Ratio PLG-PEG- 75/25 1000 - 100/0 4250 Water PLG soluble ABA 2) PLG-PEG- 75/25 1450 - 100/0 3950 Water PLG soluble (ABA 3 PLA-PEG- 100/0 1000 1450 10/90 3980 Water PLA soluble (ABA 4 PLG-PEG- 75/25 1450 - 100/0 7540 Water PLG insoluble n (ABA 5 PLA-PE- 100/0 1000 600 80/20 6500 Water PLA insoluble ABA 6) 4 _ Example 6 AB diblock copolymer was synthesized by placing 25.7 g of PEG-Me (Mw: 2000) in a 250 mL 3-neck round bottom reaction flask. Water was removed by heating in an oil bath (155 C) under vacuum (0.5 torr) for 3 hours. The reaction flask was then raised out of the oil bath and the vacuum was released.
D,L-Lactide (32.0 g) was weighed and added to the reaction flask. The headspace was replaced with dry nitrogen by repeated evacuation and flushing with dry nitrogen 5 times.
The flask was then lowered and immersed in a 155 C oil bath. Once the content was melted and the intemal temperature reached 150 C, 2 drops (200 ppm) of stannous 2-ethylhexanoate was added to initiate the polymerization. The reaction mixture was stirred using an overhead stirrer for 8 hours at a rate of 100-200 rpm. The temperature was then reduced to 140 C, and the residual monomer was removed under reduced pressure (<1 torr) over 1 hour.
The residue is a translucent, off=white solid having a molecular weight of 5450.
One gram of the diblock copolymer was added to 4 grams of PEG derivative (D
10) to afford a clear and free flowing liquid. Upon addition of the mixture to 37 C
water, the mixture turned cloudy due to apparent precipitation of the water insoluble diblock copolymeric component.
Example 7 Me-PEG (MW 550; 48.6 g) was transferred into a 250 mL 3-neck round bottom reaction flask. The oil bath was heated to 100 C. The molten PEG-Me was stirred under vacuum for 5 hours to remove water. The reaction flask was then raised outside of the oil bath and the vacuum was released. D,L-Lactide (97.68 g) and glycolide (26.47 g) were weighed and added the reaction flask. The headspace was replaced with dry nitrogen. The flask was then immersed . . ........ i . , ... .... . . .. .. . . .. ... ..... ........ ... .. ... ...
.
24 into a 155 C oil bath. Once the D,L-lactide was melted and the temperature inside the reaction flask reached 150 C, 2 drops (200 ppm) of stannous 2-ethylhexanoate was added to the reaction flask. The reaction was stirred continuously for 8 hours at a rate of 100-150 rpm.
The oil bath temperature was reduced to 140 C and the reaction flask was attached to vacuum (<I torr) for an hour to remove residual monomer. The diblock copolymer had honey-like consistency with molecular weight of 2010. The residue (145 g) was added to 1,6-diisocynatohexane (6.06 g) via an oven dried syringe and the reaction mixture was allowed to stir at 140 C for 2 additional hours. The residue was purified by dissolving the polymer in water and precipitation at 70 C. Water was removed by lyophilization and the residual BAB triblock copolymer had a molecular weight of 4250.
One gram of the polymer was dissolved in 4 gram of PEG derivative (D 4) and the mixture was added to 25 mL of warm water (37 C) via a 24-G needle. Upon addition of the mixture to 37 C water, the mixture turned cloudy due to apparent precipitation of the water insoluble diblock copolymeric component.
Example 8 The use PEG derivatives for reconstitution are illustrated in this example.
The PEG derivative(1.5 g) prepared from Example 1 were added to 1 gram of PLGA-PEG-PLGA triblock copolymer prepared from Example 4. The two components were intimately mixed into a homogeneous mixture. To the mixture, water for injection (5 g) was added shaken. The mixture took 1 minute to reconstitute. The resulting aqueous solution had a gelation temperature at 30 C and 37 C.
Zinc insulin (5 mg) was reconstituted with 5 mL of the aqueous solution and the solution was injected into 37 C water. The solution rapidly gelled.
WO 2004/002456 PCT/US2003/1)16987 Example 9 Zn-insulin (5 mg) is suspended a mixture composed of a triblock copolymer (ABA
6; 1 g) dissolved in 6 g of PEG derivative (D 2). The mixture is a free-flowing liquid. One mL of the suspension is injected into warm water (25 mL; 37 C). Upon addition of the mixture to 5 37 C water, the mixture tumed cloudy due to apparent precipitation of the water insoluble triblock copolymeric component.
Example 10 The PEG derivatives (D6; 4 g) were added to 1 gram of PLGA-PEG-PLGA triblock copolymer (ABA3). Also added to the mixture was 50 mg of paclitaxel. The mixture was 10 intimately mixed into a homogeneous mixture at ca. 40 C for ca. 20 minutes.
The mixture was a clear free flowing liquid. One gram of the mixture was added to a beaker containing 25 mL of warm water (37 C). The mixture apparently dissolved rapidly to afford a clear solution or uniform colloid.
15 Example 11 The PEG derivative(3 g) from Example 1 were intimately mixed with I gram of PLGA-PEG-PLGA triblock copolymer (ABA3) and 0.08 g of poly(D,L-lactate-co-glycolate) (MW
1200) into a homogeneous mixture. Paclitaxel (75 mg) was dissolved into the mixture with gentle stirring at ca. 45 C. After equilibrated to ambient temperature, water for injection (5 g) 20 was added and the mixture was shaken. The mixture apparently dissolved rapidly to afford a clear solution or uniform colloid.
Example 12 This example illustrate the synthesis of poly(ortho ester) AB diblock copolymer.
Dried 1,4-cyclohexanedirnethanol (2.6 g), PEG 2000 methyl ether (4 g) is heated at 70 C
.. .. .. . .~ . .. .... . .. . . _ .. . . . . . . .. .. . .... . ... . _ . . .
with DETOSU (3,9-bis(ethylidene)-2,4,8,10-tetraoxaspiro[5,5]undecane; 4.35 g) in dried 1,4-dioxane (100 mL) over 8 hour. The solvent is removed under vacuum (0.5 torr; 70 C) over 40 hours. The resulting poly(ortho ester) AB diblock copolymer is a transparent copolymer.
Example 13 This example illustrates the synthesis of PEG ortho ester derivative. PEG 300 (25.0 g) is heated in a round bottomed flask under vacuum at 90 C for 3 hours to remove residual water.
Molten DETOSU (3,9-bis(ethylidine)-2,4,8,10-tetraoxaspiro[5,5]undecane) (4.0 grams)is added to the flask through an oven dried syringe. The mixture is allowed to heat at 90 C over 5 hours.
The resulting PEG ortho ester derivative is a clear liquid.
Example 14 This example illustrates the use of PEG ortho ester derivative. Paclitaxel (50 mg) is dissolved with mild heating into a mixture of PEG derivative (15 g) synthesized in Example 13 and an AB diblock poly(ortho ester) copolymer (3 g) prepared in Example 12.
The resulting mixture is a clear liquid. Upon addition of the mixture to 37 C water, the mixture tumed cloudy due to apparent precipitation of the water insoluble diblock copolymeric component.
The above description will enable one skilled in the art to make a composition compr ising biodegradable block copolymer drug carriers and PEG, PEG
derivatives, or a mixtures thereof, said composition is a flowable liquid or can be rapidly reconstituted in an aqueous vehicle to homogeneous solutions or uniforrn colloidal systems.
Although the drug delivery compositions are described to show the functionality of the compositions of the present invention, these descriptions are not intended to be an exhaustive statement of all drug carriers that can be rendered soluble and/ox constitutable by the compositions of the present invention.
_ ,. . ,....
Certainly, numerous other drug carriers or drugs from various categories of therapeutic agents are well suited for the drug delivery compositions described in this invention. It will be immediately apparent to one skilled in the art which various modifications may be made without departing from the scope of the invention that is limited only by the following claims and their functional equivalents.
The oil bath temperature was reduced to 140 C and the reaction flask was attached to vacuum (<I torr) for an hour to remove residual monomer. The diblock copolymer had honey-like consistency with molecular weight of 2010. The residue (145 g) was added to 1,6-diisocynatohexane (6.06 g) via an oven dried syringe and the reaction mixture was allowed to stir at 140 C for 2 additional hours. The residue was purified by dissolving the polymer in water and precipitation at 70 C. Water was removed by lyophilization and the residual BAB triblock copolymer had a molecular weight of 4250.
One gram of the polymer was dissolved in 4 gram of PEG derivative (D 4) and the mixture was added to 25 mL of warm water (37 C) via a 24-G needle. Upon addition of the mixture to 37 C water, the mixture turned cloudy due to apparent precipitation of the water insoluble diblock copolymeric component.
Example 8 The use PEG derivatives for reconstitution are illustrated in this example.
The PEG derivative(1.5 g) prepared from Example 1 were added to 1 gram of PLGA-PEG-PLGA triblock copolymer prepared from Example 4. The two components were intimately mixed into a homogeneous mixture. To the mixture, water for injection (5 g) was added shaken. The mixture took 1 minute to reconstitute. The resulting aqueous solution had a gelation temperature at 30 C and 37 C.
Zinc insulin (5 mg) was reconstituted with 5 mL of the aqueous solution and the solution was injected into 37 C water. The solution rapidly gelled.
WO 2004/002456 PCT/US2003/1)16987 Example 9 Zn-insulin (5 mg) is suspended a mixture composed of a triblock copolymer (ABA
6; 1 g) dissolved in 6 g of PEG derivative (D 2). The mixture is a free-flowing liquid. One mL of the suspension is injected into warm water (25 mL; 37 C). Upon addition of the mixture to 5 37 C water, the mixture tumed cloudy due to apparent precipitation of the water insoluble triblock copolymeric component.
Example 10 The PEG derivatives (D6; 4 g) were added to 1 gram of PLGA-PEG-PLGA triblock copolymer (ABA3). Also added to the mixture was 50 mg of paclitaxel. The mixture was 10 intimately mixed into a homogeneous mixture at ca. 40 C for ca. 20 minutes.
The mixture was a clear free flowing liquid. One gram of the mixture was added to a beaker containing 25 mL of warm water (37 C). The mixture apparently dissolved rapidly to afford a clear solution or uniform colloid.
15 Example 11 The PEG derivative(3 g) from Example 1 were intimately mixed with I gram of PLGA-PEG-PLGA triblock copolymer (ABA3) and 0.08 g of poly(D,L-lactate-co-glycolate) (MW
1200) into a homogeneous mixture. Paclitaxel (75 mg) was dissolved into the mixture with gentle stirring at ca. 45 C. After equilibrated to ambient temperature, water for injection (5 g) 20 was added and the mixture was shaken. The mixture apparently dissolved rapidly to afford a clear solution or uniform colloid.
Example 12 This example illustrate the synthesis of poly(ortho ester) AB diblock copolymer.
Dried 1,4-cyclohexanedirnethanol (2.6 g), PEG 2000 methyl ether (4 g) is heated at 70 C
.. .. .. . .~ . .. .... . .. . . _ .. . . . . . . .. .. . .... . ... . _ . . .
with DETOSU (3,9-bis(ethylidene)-2,4,8,10-tetraoxaspiro[5,5]undecane; 4.35 g) in dried 1,4-dioxane (100 mL) over 8 hour. The solvent is removed under vacuum (0.5 torr; 70 C) over 40 hours. The resulting poly(ortho ester) AB diblock copolymer is a transparent copolymer.
Example 13 This example illustrates the synthesis of PEG ortho ester derivative. PEG 300 (25.0 g) is heated in a round bottomed flask under vacuum at 90 C for 3 hours to remove residual water.
Molten DETOSU (3,9-bis(ethylidine)-2,4,8,10-tetraoxaspiro[5,5]undecane) (4.0 grams)is added to the flask through an oven dried syringe. The mixture is allowed to heat at 90 C over 5 hours.
The resulting PEG ortho ester derivative is a clear liquid.
Example 14 This example illustrates the use of PEG ortho ester derivative. Paclitaxel (50 mg) is dissolved with mild heating into a mixture of PEG derivative (15 g) synthesized in Example 13 and an AB diblock poly(ortho ester) copolymer (3 g) prepared in Example 12.
The resulting mixture is a clear liquid. Upon addition of the mixture to 37 C water, the mixture tumed cloudy due to apparent precipitation of the water insoluble diblock copolymeric component.
The above description will enable one skilled in the art to make a composition compr ising biodegradable block copolymer drug carriers and PEG, PEG
derivatives, or a mixtures thereof, said composition is a flowable liquid or can be rapidly reconstituted in an aqueous vehicle to homogeneous solutions or uniforrn colloidal systems.
Although the drug delivery compositions are described to show the functionality of the compositions of the present invention, these descriptions are not intended to be an exhaustive statement of all drug carriers that can be rendered soluble and/ox constitutable by the compositions of the present invention.
_ ,. . ,....
Certainly, numerous other drug carriers or drugs from various categories of therapeutic agents are well suited for the drug delivery compositions described in this invention. It will be immediately apparent to one skilled in the art which various modifications may be made without departing from the scope of the invention that is limited only by the following claims and their functional equivalents.
Claims (5)
1. A composition comprising:
1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block copolymers having a total weight average molecular weight of 2000 to 4990 Daltons, wherein the A block is a biodegradable polyester or poly (ortho ester) and the B block is polyethylene glycol (PEG), and the weight percentage of the A block is between 51% to 83% and the weight percentage of the B block is between 17% to 49%; and
1) one or more biodegradable block copolymer drug carriers comprising A-B, A-B-A or B-A-B block copolymers having a total weight average molecular weight of 2000 to 4990 Daltons, wherein the A block is a biodegradable polyester or poly (ortho ester) and the B block is polyethylene glycol (PEG), and the weight percentage of the A block is between 51% to 83% and the weight percentage of the B block is between 17% to 49%; and
2) a polyethylene glycol (PEG), a PEG derivative, or a mixture of PEG and a PEG derivative, said PEG or PEG derivative having a molecular weight of 150 to 1100 Daltons;
wherein at least one of the one or more biodegradable block copolymer drug carriers is soluble in an aqueous solution and miscible with the PEG, PEG derivatives, or mixtures thereof;
wherein the weight ratio of the biodegradable block copolymer drug carrier and the PEG, PEG derivative or mixtures thereof is within the range of 5:1 to 1:99 and wherein said composition can be reconstituted in water or an aqueous solution to form a homogeneous solution or a uniform colloidal system within 0.01 minutes to 180 minutes; and wherein the composition possesses reverse thermal gelation properties.
2. The composition according to Claim 1, wherein the PEG derivative is an ortho ester derivatized PEG.
wherein at least one of the one or more biodegradable block copolymer drug carriers is soluble in an aqueous solution and miscible with the PEG, PEG derivatives, or mixtures thereof;
wherein the weight ratio of the biodegradable block copolymer drug carrier and the PEG, PEG derivative or mixtures thereof is within the range of 5:1 to 1:99 and wherein said composition can be reconstituted in water or an aqueous solution to form a homogeneous solution or a uniform colloidal system within 0.01 minutes to 180 minutes; and wherein the composition possesses reverse thermal gelation properties.
2. The composition according to Claim 1, wherein the PEG derivative is an ortho ester derivatized PEG.
3. The composition according to Claim 1, wherein the PEG derivative is represented by R1-CO-O-(CH2-CH2-O)n-CO-R2 or R1-O-(CH2-CH2-O)n-R2 wherein R1 and R2 are independently H and C1 to C10 alkyl and n is an integer between 3 and 20.
4. The composition according to Claim 1, further comprising a drug.
5. The composition according to Claim 1, wherein the PEG derivative is an ester derivatized PEG wherein the PEG is derivatized with D,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, .epsilon.-caprolactone, 1,4-dioxan-2-one, .epsilon.-hydroxy hexanoic acid, .gamma.-butyrolactone, y-hydroxy butyric acid, .delta.-valerolactone, .delta.-hydroxy valeric acid, hydroxybutyric acids, malic acid, or mixtures thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/186,462 | 2002-06-28 | ||
US10/186,462 US7649023B2 (en) | 2002-06-11 | 2002-06-28 | Biodegradable block copolymeric compositions for drug delivery |
CA002489771A CA2489771A1 (en) | 2002-06-28 | 2003-05-29 | Biodegradable block copolymeric compositions for drug delivery |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002489771A Division CA2489771A1 (en) | 2002-06-28 | 2003-05-29 | Biodegradable block copolymeric compositions for drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2672551A1 true CA2672551A1 (en) | 2004-01-08 |
CA2672551C CA2672551C (en) | 2013-02-05 |
Family
ID=29779889
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2672551A Expired - Fee Related CA2672551C (en) | 2002-06-28 | 2003-05-29 | Biodegradable block copolymeric compositions for drug delivery |
CA002489771A Abandoned CA2489771A1 (en) | 2002-06-28 | 2003-05-29 | Biodegradable block copolymeric compositions for drug delivery |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002489771A Abandoned CA2489771A1 (en) | 2002-06-28 | 2003-05-29 | Biodegradable block copolymeric compositions for drug delivery |
Country Status (8)
Country | Link |
---|---|
US (4) | US7649023B2 (en) |
EP (2) | EP1531797A4 (en) |
JP (2) | JP2005535638A (en) |
KR (2) | KR20050058291A (en) |
CN (2) | CN101890168A (en) |
AU (1) | AU2003237288A1 (en) |
CA (2) | CA2672551C (en) |
WO (1) | WO2004002456A1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1032662E (en) * | 1997-11-07 | 2006-07-31 | Trillium Therapeutics Inc | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION. |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7763769B2 (en) * | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
US20030228366A1 (en) * | 2002-06-11 | 2003-12-11 | Chung Shih | Reconstitutable compositions of biodegradable block copolymers |
AU2004224413A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Prostaglandin compositions for the treatment of erectile dysfunction |
CA2536096A1 (en) * | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
US8980300B2 (en) | 2004-08-05 | 2015-03-17 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
JP2008509935A (en) * | 2004-08-13 | 2008-04-03 | アンジオテック インターナショナル アーゲー | Compositions and methods using hyaluronic acid and hyaluronic acid inhibitors |
US20060034889A1 (en) * | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
US7597907B2 (en) * | 2004-11-05 | 2009-10-06 | Trustees Of The University Of Pennsylvania | Antioxidant polymer nanocarriers for use in preventing oxidative injury |
US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
KR20070095921A (en) | 2004-12-10 | 2007-10-01 | 탈리마 테라퓨틱스 인코포레이티드 | Compositions and methods for treating conditions of the nail unit |
CA2618404A1 (en) * | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
KR101529318B1 (en) * | 2005-12-19 | 2015-06-16 | 파마인 코포레이션 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
EP2044142A2 (en) * | 2006-06-29 | 2009-04-08 | Medtronic, Inc. | Poly(orthoester) polymers, and methods of making and using same |
GB0620685D0 (en) * | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
CA2668814A1 (en) * | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
US20080114076A1 (en) * | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
KR100932613B1 (en) * | 2007-04-27 | 2009-12-17 | 한남대학교 산학협력단 | Preparation of nanospheres composed of biocompatible polymers using polymer melt process for drug delivery and nanospheres thereof |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
US8178617B2 (en) | 2007-07-16 | 2012-05-15 | Allvivo Vascular, Inc. | Antimicrobial constructs |
US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
US20110129514A1 (en) * | 2007-09-06 | 2011-06-02 | Hossainy Syed F A | Hygroscopic coating on a balloon device |
US8568786B2 (en) * | 2007-10-27 | 2013-10-29 | The Trustees Of The Universtiy Of Pennsylvania | Method and compositions for polymer nanocarriers containing therapeutic molecules |
US7927629B2 (en) * | 2007-10-27 | 2011-04-19 | The Trustees Of The University Of Pennsylvania | Method and compositions for polymer nanocarriers containing therapeutic molecules |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
US20090285873A1 (en) * | 2008-04-18 | 2009-11-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide) |
US8940315B2 (en) * | 2008-04-18 | 2015-01-27 | Medtronic, Inc. | Benzodiazepine formulation in a polyorthoester carrier |
US8956642B2 (en) * | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
CA2756072A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
US9155722B2 (en) * | 2009-09-18 | 2015-10-13 | Protherics Salt Lake City, Inc. | Reconstitutable reverse thermal gelling polymers |
RU2565668C2 (en) * | 2009-09-18 | 2015-10-20 | Протерикс Медисинс Дивелопмент Лимитед | Polymers capable of recovery and reversible thermal gel-formation |
US9504698B2 (en) * | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
US8470891B2 (en) * | 2009-12-23 | 2013-06-25 | International Business Machines Corporation | Biodegradable block polymers for drug delivery, and methods related thereto |
US9295663B2 (en) | 2010-07-14 | 2016-03-29 | Abbott Cardiovascular Systems Inc. | Drug coated balloon with in-situ formed drug containing microspheres |
AU2011337139B2 (en) | 2010-08-30 | 2015-11-12 | President And Fellows Of Harvard College | Shear controlled release for stenotic lesions and thrombolytic therapies |
WO2012052527A1 (en) | 2010-10-20 | 2012-04-26 | Dsm Ip Assets B.V. | Pendant hydrophile bearing biodegradable compositions and related devices |
EP3586825B1 (en) * | 2010-12-29 | 2023-01-18 | Medincell S.A. | Biodegradable drug delivery compositions |
CN103998069A (en) * | 2011-10-17 | 2014-08-20 | 聚合-医药有限公司 | Absorbable in situ gel-forming system, method of making and use thereof |
US8936784B2 (en) | 2011-10-17 | 2015-01-20 | Poly-Med, Inc. | Absorbable in situ gel-forming system, method of making and use thereof |
MX353280B (en) * | 2012-06-27 | 2018-01-05 | Medincell | Biodegradable drug delivery for hydrophobic compositions. |
WO2014159060A1 (en) | 2013-03-14 | 2014-10-02 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
DK3137532T3 (en) | 2014-05-01 | 2021-08-02 | Ingell Tech Holding B V | FLOATING TRIBLOCK COPOLYMER |
EP3207069B1 (en) * | 2014-10-15 | 2021-03-10 | University Of Connecticut | Bio-reducible self-assembled liquid crystalline block copolymer for drug delivery |
KR20160117050A (en) | 2015-03-31 | 2016-10-10 | 홍익대학교세종캠퍼스산학협력단 | Microgel comprising biodegradable polymer and method for preparing the same |
FI3377041T3 (en) | 2015-11-16 | 2023-11-30 | Medincell S A | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
AU2018238136A1 (en) | 2017-03-20 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
WO2018183624A1 (en) | 2017-03-29 | 2018-10-04 | The Regents Of The University Of Colorado, A Body Corporate | Reverse thermal gels and their use as vascular embolic repair agents |
CN107163255B (en) * | 2017-04-21 | 2020-10-20 | 四川大学 | Redox and pH dual-response random-graft type drug carrier and method |
AU2018285975B2 (en) | 2017-06-13 | 2023-11-16 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
CN107410295B (en) * | 2017-06-19 | 2020-10-16 | 扬州大学 | Azoxystrobin water suspending agent with particle size less than 100 nanometers and preparation method thereof |
BR112020001031A2 (en) | 2017-07-17 | 2020-07-14 | Medincell | mixtures of biodegradable drug release compositions to modulate the drug release kinetics of at least one active ingredient |
JP7017770B2 (en) * | 2017-07-31 | 2022-02-09 | 国立大学法人 東京大学 | Depolymerizable amphipathic block copolymer |
GB201900258D0 (en) * | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
KR102326634B1 (en) * | 2019-12-24 | 2021-11-15 | 주식회사 현대바이오랜드 | Manufacturing method block copolymer for preparing nanoemulsion containing high content |
US20230210783A1 (en) * | 2020-06-12 | 2023-07-06 | Rutgers, The State University Of New Jersey | Nanosphere size control by varying the ratio of copolymer blends |
CA3194232A1 (en) | 2020-09-29 | 2022-04-07 | Daniel Beard | Stroke treatment |
WO2023177300A1 (en) | 2022-03-17 | 2023-09-21 | InnoCore Technologies Holding B.V. | Biodegradable thermoplastic poly(ortho ester) based multiblock copolymers |
WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
EP0071324B1 (en) * | 1981-07-31 | 1985-06-26 | Tokyo Sintered Metal Co., Ltd. | Method of manufacturing vent element |
ATE37983T1 (en) | 1982-04-22 | 1988-11-15 | Ici Plc | DELAYED RELEASE AGENT. |
US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
GB8416234D0 (en) | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
US4716203A (en) | 1986-09-05 | 1987-12-29 | American Cyanamid Company | Diblock and triblock copolymers |
EP0258780B1 (en) | 1986-09-05 | 1993-06-23 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
US5143661A (en) | 1987-05-26 | 1992-09-01 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules |
US5123912A (en) | 1987-08-26 | 1992-06-23 | United States Surgical Corporation | Absorbable coating composition, coated sutures and method of preparation |
US4830855A (en) | 1987-11-13 | 1989-05-16 | Landec Labs, Inc. | Temperature-controlled active agent dispenser |
JP2670680B2 (en) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | Polylactic acid microspheres containing physiologically active substance and method for producing the same |
JPH064540B2 (en) | 1988-09-14 | 1994-01-19 | 多木化学株式会社 | Medical composition |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5681576A (en) | 1988-11-16 | 1997-10-28 | Mdv Technologies, Inc. | Method and composition for post surgical adhesion reduction |
US4911926A (en) | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
JPH0383914A (en) | 1989-08-18 | 1991-04-09 | W R Grace & Co | Drug carrier |
US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5143731A (en) | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5124151A (en) | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
US5202352A (en) | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
ZA918526B (en) | 1990-10-30 | 1992-08-26 | Alza Corp | Drug delivery system and method |
JP3067262B2 (en) * | 1991-03-19 | 2000-07-17 | 大日本インキ化学工業株式会社 | Flame retardant thermoplastic resin composition and flame retardant for thermoplastic resin |
FR2678168B1 (en) | 1991-06-28 | 1993-09-03 | Rhone Poulenc Rorer Sa | NANOPARTICLES HAVING CAPTURE TIME BY THE EXTENDED RETICULO ENDOTHELIAL DYSTEM. |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
DK0543584T3 (en) * | 1991-11-18 | 1996-07-01 | Lilly Industries Ltd | Benzo (b) thiophene-2-carboxamides for the treatment of central nervous system disorders |
US5260066A (en) | 1992-01-16 | 1993-11-09 | Srchem Incorporated | Cryogel bandage containing therapeutic agent |
CA2129514A1 (en) | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
US5384333A (en) | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
US6514533B1 (en) | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
US5312437A (en) | 1992-06-12 | 1994-05-17 | United States Surgical Corporation | Absorbable coating composition and suture coated therewith |
WO1994007469A1 (en) | 1992-09-25 | 1994-04-14 | Dynagen, Inc. | An immunobooster for delayed release of immunogen |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5308501A (en) * | 1993-04-02 | 1994-05-03 | Eckert C Edward | Treatment system for alkaline or acidic solution containing heavy metals |
EP2226085B1 (en) | 1993-07-19 | 2013-11-27 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US20030203976A1 (en) | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
JP3220331B2 (en) | 1993-07-20 | 2001-10-22 | エチコン・インコーポレーテツド | Absorbable liquid copolymers for parenteral administration |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5560993A (en) * | 1994-02-16 | 1996-10-01 | Mitsubishi Jukogyo Kabushiki Kaisha | Oxide-coated silicon carbide material and method of manufacturing same |
DE4406172C2 (en) | 1994-02-25 | 2003-10-02 | Sanol Arznei Schwarz Gmbh | polyester |
DK1125577T3 (en) | 1994-04-08 | 2006-06-19 | Qlt Usa Inc | Liquid drug delivery preparations |
KR0141431B1 (en) | 1994-05-17 | 1998-07-01 | 김상웅 | Biodegradable hydrogel copolymer |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5607686A (en) | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6551610B2 (en) | 1995-04-13 | 2003-04-22 | Poly-Med, Inc. | Multifaceted compositions for post-surgical adhesion prevention |
GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
WO1997005185A2 (en) | 1995-07-28 | 1997-02-13 | Focal, Inc. | Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents |
KR0180334B1 (en) | 1995-09-21 | 1999-03-20 | 김윤 | Drug messenger using el-2l-2 micelle and method for sealing drug to it |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
FR2741628B1 (en) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | NOVEL HYDROGELS BASED ON TRISQUENCY COPOLYMERS AND THEIR APPLICATION IN PARTICULAR TO THE PROGRESSIVE RELEASE OF ACTIVE INGREDIENTS |
US6280745B1 (en) | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
US5711958A (en) | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
AU5609798A (en) | 1996-12-20 | 1998-07-17 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6841617B2 (en) | 2000-09-28 | 2005-01-11 | Battelle Memorial Institute | Thermogelling biodegradable aqueous polymer solution |
US5939453A (en) * | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
EP1109563A4 (en) | 1998-08-04 | 2009-07-22 | Madash Llp | End modified thermal responsive hydrogels |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6451346B1 (en) | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US6923966B2 (en) * | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
US6579951B1 (en) | 1999-06-08 | 2003-06-17 | Life Medical Sciences, Inc. | Chain-extended or crosslinked polyethylene oxide/polypropylene oxide/polyethylene oxide block polymer with optional polyester blocks |
KR100360827B1 (en) | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
PT1207860E (en) | 1999-09-02 | 2008-01-24 | Nostrum Pharmaceuticals Inc | Controlled release pellet formulation |
KR100416242B1 (en) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | Liquid composition of biodegradable block copolymer for drug delivery and process for the preparation thereof |
AU4455301A (en) | 2000-03-21 | 2001-10-03 | Sunao Kubota | Coating materials for biological tissues, coated biological tissues and method of coating biological tissues |
US7018645B1 (en) * | 2000-04-27 | 2006-03-28 | Macromed, Inc. | Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6660247B1 (en) | 2000-06-23 | 2003-12-09 | Battelle Memorial Institute | Multiple stimulus reversible hydrogels |
WO2002030466A2 (en) | 2000-10-11 | 2002-04-18 | Purdue Research Foundation | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof |
US6748954B2 (en) | 2000-10-27 | 2004-06-15 | The Regents Of The University Of Michigan | Drug release from polymer matrices through mechanical stimulation |
KR100446101B1 (en) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | Sustained delivery composition for poorly water soluble drugs |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US20040185101A1 (en) | 2001-03-27 | 2004-09-23 | Macromed, Incorporated. | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof |
US20030003074A1 (en) | 2001-06-14 | 2003-01-02 | Macromed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
US6623729B2 (en) | 2001-07-09 | 2003-09-23 | Korea Advanced Institute Of Science And Technology | Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer |
IL151288A0 (en) | 2001-08-27 | 2003-04-10 | Yissum Res Dev Co | Multi-component reverse thermo-sensitive polymeric systems |
US6592899B2 (en) | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
US8740973B2 (en) | 2001-10-26 | 2014-06-03 | Icon Medical Corp. | Polymer biodegradable medical device |
US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
US20030228366A1 (en) * | 2002-06-11 | 2003-12-11 | Chung Shih | Reconstitutable compositions of biodegradable block copolymers |
KR100502840B1 (en) | 2002-09-04 | 2005-07-21 | 학교법인 포항공과대학교 | A block copolymer micelle composition having an improved drug loading capacity |
CA2511486A1 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Tissue reactive compounds and compositions and uses thereof |
CN1446833A (en) | 2003-02-08 | 2003-10-08 | 复旦大学 | Warm sensitivity degradable micro gelatin and its preparation method |
US20050058688A1 (en) | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
JP4459543B2 (en) | 2003-03-17 | 2010-04-28 | 株式会社メドジェル | Sustained release hydrogel formulation |
US20040253293A1 (en) | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
US7179867B2 (en) | 2003-11-26 | 2007-02-20 | Industrial Technology Research Institute | Thermosensitive biodegradable copolymer |
JP2007517042A (en) | 2003-12-30 | 2007-06-28 | デュレクト コーポレーション | Polymer implant for the controlled release of an active substance, preferably GNRH, preferably containing a mixture of PEG and PLG |
US8357391B2 (en) | 2004-07-30 | 2013-01-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
TWI294098B (en) * | 2004-08-06 | 2008-03-01 | Via Tech Inc | Fast boot method and system |
US20060034899A1 (en) | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
US20060046960A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
JP4654641B2 (en) * | 2004-09-15 | 2011-03-23 | オムロンヘルスケア株式会社 | Sphygmomanometer cuff |
WO2006039659A1 (en) | 2004-10-02 | 2006-04-13 | Sri International | Bioadhesive delivery system for transmucosal delivery of beneficial agents |
KR100912307B1 (en) | 2004-10-21 | 2009-08-14 | 유니버시티 오브 아이오와 리써치 파운데이션 | In situ controlled release drug delivery system |
US8246949B2 (en) | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
US20060093639A1 (en) | 2004-10-29 | 2006-05-04 | Starkebaum Warren L | Method and device for destroying body tissue |
EP1898880A2 (en) | 2005-06-16 | 2008-03-19 | Warner Chilcott Company Inc. | Gel compositions for topical administration |
JP6415598B2 (en) | 2014-12-18 | 2018-10-31 | 堺ディスプレイプロダクト株式会社 | Display device |
-
2002
- 2002-06-28 US US10/186,462 patent/US7649023B2/en not_active Expired - Lifetime
-
2003
- 2003-05-29 JP JP2004517595A patent/JP2005535638A/en active Pending
- 2003-05-29 WO PCT/US2003/016987 patent/WO2004002456A1/en active Application Filing
- 2003-05-29 AU AU2003237288A patent/AU2003237288A1/en not_active Abandoned
- 2003-05-29 CN CN200910151700XA patent/CN101890168A/en active Pending
- 2003-05-29 KR KR1020047021037A patent/KR20050058291A/en not_active Application Discontinuation
- 2003-05-29 CA CA2672551A patent/CA2672551C/en not_active Expired - Fee Related
- 2003-05-29 EP EP03736754A patent/EP1531797A4/en not_active Withdrawn
- 2003-05-29 KR KR1020097015575A patent/KR100933580B1/en not_active IP Right Cessation
- 2003-05-29 CA CA002489771A patent/CA2489771A1/en not_active Abandoned
- 2003-05-29 CN CNB038181746A patent/CN100540055C/en not_active Expired - Fee Related
- 2003-05-29 EP EP09009993.8A patent/EP2106787B1/en not_active Expired - Lifetime
-
2009
- 2009-06-24 US US12/490,968 patent/US8642666B2/en not_active Expired - Lifetime
- 2009-07-23 JP JP2009171750A patent/JP5121790B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,175 patent/US20100076067A1/en not_active Abandoned
-
2013
- 2013-12-23 US US14/139,148 patent/US9265836B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20140113975A1 (en) | 2014-04-24 |
EP2106787A3 (en) | 2010-10-13 |
JP5121790B2 (en) | 2013-01-16 |
KR100933580B1 (en) | 2009-12-22 |
CN100540055C (en) | 2009-09-16 |
EP2106787A2 (en) | 2009-10-07 |
US20100076067A1 (en) | 2010-03-25 |
CN1671362A (en) | 2005-09-21 |
US8642666B2 (en) | 2014-02-04 |
CA2489771A1 (en) | 2004-01-08 |
KR20050058291A (en) | 2005-06-16 |
US9265836B2 (en) | 2016-02-23 |
JP2005535638A (en) | 2005-11-24 |
US20040001872A1 (en) | 2004-01-01 |
KR20090086478A (en) | 2009-08-12 |
WO2004002456A1 (en) | 2004-01-08 |
EP1531797A4 (en) | 2007-05-30 |
CA2672551C (en) | 2013-02-05 |
US20090264537A1 (en) | 2009-10-22 |
CN101890168A (en) | 2010-11-24 |
JP2009280600A (en) | 2009-12-03 |
US7649023B2 (en) | 2010-01-19 |
EP2106787B1 (en) | 2020-05-13 |
EP1531797A1 (en) | 2005-05-25 |
AU2003237288A1 (en) | 2004-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2672551C (en) | Biodegradable block copolymeric compositions for drug delivery | |
US6592899B2 (en) | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water | |
US6117949A (en) | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties | |
AU736812B2 (en) | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties | |
CA2577432C (en) | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof | |
CA2345659C (en) | Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties | |
EP1276505A1 (en) | Mixtures of triblock polyesterpolyethylene glycol copolymers | |
US20040185101A1 (en) | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof | |
US20030228366A1 (en) | Reconstitutable compositions of biodegradable block copolymers | |
US20020192286A1 (en) | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190529 |